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the molecular motor dynein and enzymatic function as an E3 ubiquitin ligase in promoting its
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persistence of fetal hemoglobin, a benign condition that ameliorates co-inherited sickle cell disease
(SCD). Genome editing in human hematopoietic stem and progenitor cells reversed the hemoglobin
switch at levels sufficient in vitro to correct pathological morphologies in SCD patient-derived RBCs. We
identify a cis-regulatory element in the γ-globin promoter as a potential target for genome-editing therapy
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variants to uncover new aspects of erythroid biology.
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ABSTRACT

INSIGHTS INTO TERMINAL ERYTHROPOIESIS INFLUENCED BY
HUMAN GENETIC VARIATION
Elizabeth A. Traxler
Dr. Mitchell Weiss

Red blood cells (RBCs) carry hemoglobin, enabling delivery of oxygen to all
tissues of the body. They are the products of a highly specialized differentiation process
that begins with a hematopoietic stem cell and results in an enucleated, biconcave RBC.
This thesis is focused on the use of human genetic studies to gain a better understanding
of the molecular processes occurring during terminal erythroid differentiation. We
studied the regulation and roles of two erythroid-restricted genes, Trim58 and
Hemoglobin Gamma Chain (HBG1 and HBG2, γ-globin), by using a combination of lossof-function techniques, including RNA-interference-mediated gene suppression, a mutant
mouse model, and CRISPR/Cas9 mediated genome editing. Previous genome-wide
association studies implicated variation in TRIM58 in RBC development and function.
Our experiments with Trim58 revealed a direct interaction with the molecular motor
dynein and enzymatic function as an E3 ubiquitin ligase in promoting its proteasomal
degradation. This interaction is necessary for enucleation in knockdown studies in vitro,
iv

but genetic studies in the mouse show Trim58 is not required for erythropoiesis or
enucleation. In the second part of this thesis, we used CRISPR/Cas9 to recreate a known
mutation associated with hereditary persistence of fetal hemoglobin, a benign condition
that ameliorates co-inherited sickle cell disease (SCD). Genome editing in human
hematopoietic stem and progenitor cells reversed the hemoglobin switch at levels
sufficient in vitro to correct pathological morphologies in SCD patient-derived RBCs. We
identify a cis-regulatory element in the γ-globin promoter as a potential target for
genome-editing therapy for SCD. Together, these findings underscore the importance of
utilizing both common and rare genetic variants to uncover new aspects of erythroid
biology.
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Preface

This thesis is a series of chapters based on published and submitted manuscripts, and the
results are organized and presented closely to how they were published. Each chapter
begins with a statement explaining the motivating factors driving the studies, and closes
with a brief reflective commentary. Chapter 6 contains more in-depth analysis on the
work through a retrospective lens.
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Chapter 1 Introduction

1.1 Red blood cell function
Circulating red blood cells (RBC), or erythrocytes, deliver oxygen (O2) to all tissues
of the body. Each mature cell is comprised of ~340 mg/mL hemoglobin (Hb), a hemecontaining metalloprotein complex accounting for over 90% of the cellular protein
composition (Roux-Dalvai et al., 2008). Hb is a heterotetrameric complex of two α- and
two β-like globin subunits or chains, which are each coordinated to a heme. Each heme
coordinates an O2 molecule and allows efficient off-loading to deoxygenated tissues.
While Hb is the universal O2 carrier, packaging high levels of Hb in the form of cells is
advantageous for mammalian life in contrast to invertebrate O2 transport, which relies on
via free, high-molecular-weight Hb. If vertebrates also lacked an efficient Hb packaging
strategy, extremely high oncotic pressure would preclude a closed circulatory system.

1.2 Erythropoiesis
Erythropoiesis is developmentally divided into three waves, based on erythrocyte
size, tissue of origin, and type of hemoglobin expressed. Two main functional
requirements highlight the differences between embryonic and adult erythropoiesis. In
the embryo, RBCs are required before long-term hematopoietic stem cell (HSC)
populations and their environmental niches are established. Additionally, the rapid
growth during embryogenesis demands dramatic red cell output (McGrath and Palis,
1

2008). In contrast, adult erythropoiesis normally remains at steady state in the absence of
a hematopoietic stressor such as hemorrhage or hemolysis. The first wave, the primitive
wave, begins in the yolk sac and yields RBCs expressing embryonic globin genes (Palis
et al., 1995; Silver and Palis, 1997). Until recently, these RBCs were assumed to remain
nucleated, but both human and murine primitive erythroblasts enucleate in circulation
(McGrath et al., 2008). The second wave consists of erythro-myeloid progenitors from
the yolk sac, which can produce RBCs, platelets, and some myeloid lineages (Palis et al.,
1999; Wong et al., 1986). These progenitors ultimately migrate and seed the fetal liver
mid-gestation for the third wave, definitive erythropoiesis (Lux et al., 2008; McGrath et
al., 2015; 2011). Definitive erythropoiesis ultimately takes place in the bone marrow
through adulthood, and cells are derived from HSCs. Human definitive RBCs initially
express fetal hemoglobin (HbF, α2γ2) and post-natally express adult hemoglobin (HbA,
α2β2).

1.3 Terminal erythroid differentiation
Definitive erythroid cells are derived from HSCs, which proliferate and
differentiate into all blood lineages. The committed erythroid progenitors are burstforming unit erythroid (BFU-E) and colony-forming unit erythroid (CFU-E) cells, based
on their capacity to form colonies in semi-solid media. CFU-E committed progenitors
then undergo 4-5 specialized cell divisions, wherein gene expression profiles and cell
morphology change dramatically.
2

Figure 1.1. Terminal erythropoiesis.
Morphological features of the characteristic progression from erythroid progenitors
(BFU-E and CFU-E) to the enucleated reticulocyte and erythrocyte. Micrographs
courtesy of James Palis, adapted from Max Pimkin.

Gene expression changes
Several groups have performed global transcriptome analysis at various stages of
erythroid differentiation in primary cells (An et al., 2014; Liang et al., 2015;
Merryweather-Clarke et al., 2011; Pishesha et al., 2014) and in erythroid cell lines
(Pimkin et al., 2014; Stonestrom et al., 2015; Welch et al., 2004). A generalized
repression of RNA production occurs during terminal erythroid differentiation,
coinciding with the timing of hemoglobin synthesis. One such RNA-sequencing study of
fluorescence-activated cell sorting (FACS)-enriched human erythroblast populations
revealed 9,606 genes expressed in proerythroblasts, compared to 4,804 genes in
orthochromatic erythroblasts (An et al., 2014). Of note, about 2,000 of these genes
increased in expression over the course of erythroid differentiation. These changes in
3

gene expression are facilitated by alterations of the transcriptional network. GATA1 and
TAL1 are “master” erythroid transcriptional factors that activate essentially all erythroidspecific genes and silence those associated with a less mature, proliferative state. Genes
that are most highly induced during maturation are those related to hemoglobin synthesis,
structure, and function, including the globin genes, δ-aminolevulinate synthase 2
(ALAS2), a hemoglobin stabilizing protein (AHSP), and transferrin receptor (CD71) (An
et al., 2014).

Cellular and nuclear morphological changes
Visible morphological changes enable categorization of erythroid progenitors into
the various stages – basophilic erythroblasts, polychromatic erythroblasts, orthochromatic
erythroblasts, and finally the anucleated reticulocyte. Erythroblasts gradually decrease in
cell size and incrementally demonstrate less basophilia with histologic staining, as
hemoglobin (stains pink) production increases and ribosomes (stain blue) are eliminated.
Nuclear condensation
During erythroid differentiation and maturation, large nuclei are actively reduced
into condensed, transcriptionally inactive nuclei about 1/10th of original volume. Efficient
nuclear condensation is required for downstream enucleation (Hattangadi et al., 2014;
Jayapal et al., 2010; Ji et al., 2010; Zhao et al., 2016). This process is mediated in part by
epigenetic changes. Multiple studies highlighted the roles of histone deacetylation,
4

removal of acetyl groups from histone tails, which stabilizes chromatin and promotes
heterochromatin formation. HDAC2 chemical inhibition or knockdown prevents
chromatin condensation and larger nuclei in primary cells (Ji et al., 2010; Popova et al.,
2009). Concordantly, c-Myc downregulation of the histone acetyltransferase Gcn5 was
necessary for nuclear condensation. Ectopic expression of either c-Myc or Gcn5 inhibited
condensation and increased nuclear size (Jayapal et al., 2010). These factors function
inside the nucleus and promote chromatin compaction.
In addition to processes inside the nucleus, recent studies suggest that histones
and nuclear proteins are actively transported into the cytoplasm to aid nuclear
condensation. Xpo7 (exportin-7) is induced during late erythropoiesis, and shRNAmediated, loss-of-function studies in fetal liver erythroblasts showed that Xpo7-deficient
erythroblasts sustained larger nuclei, possibly due to retention of nuclear proteins within
the nucleus (Hattangadi et al., 2014). Furthermore, Zhao et al. recently reported the
presence of dynamic openings in the nuclear membrane, detected by discontinuous lamin
B immunostaining during late erythropoiesis (Zhao et al., 2016). Inhibition of the
openings by caspase-3 enzyme blockade or genetic disruption also resulted in increased
nuclear size and prevented cytosolic histone release.

5

Enucleation
Orthochromatic erythroblasts exit the cell cycle and undergo enucleation, where
the condensed nucleus separates into an anucleated reticulocyte (Sankaran et al., 2008b).
The expelled nucleus is surrounded by a lipid bilayer membrane, contains a thin
cytoplasm, and is called a pyrenocyte (E and D, 1967; Simpson and Kling, 1967). A
growing body of evidence parallels enucleation with an asymmetric cell division, as
several structures similar to those crucial in mitosis have been identified in enucleating
erythroblasts. Additionally, early electron microscopy demonstrated that enucleation does
not involve exocytosis, as a thin layer of cytoplasm and plasma membrane surround the
extruded nuclei (E and D, 1967; Simpson and Kling, 1967). The fate of the pyrenocyte is
nearly immediate engulfment by macrophages in the bone marrow. The pyrenocyte
membrane is highly enriched with phosphatidyl-serine, allowing direct recognition by the
macrophage (Yoshida et al., 2005).
The first morphological step of enucleation is polarization of the nucleus from a
central to peripheral location in the cell. This process is largely mediated by
microtubules. Treatment of late-stage erythroblasts with nocodozole or colchicine
depolymerizes microtubules and leaves the nucleus in the middle of the cell
(Konstantinidis et al., 2012). Exposure to taxol stabilizes microtubules and thickens the
microtubule bundles surrounding the nucleus. Both destabilizing and stabilizing
microtubules, however, inhibited enucleation (Konstantinidis et al., 2012).

While

microtubules play a structural role in the physical movements of the nucleus, they also
6

regulate local concentrations of secondary messengers to mediate polarization.
Phosphoinositide 3-kinase (PI3K) is an important kinase which activates secondary
messengers phosphatidyl-inositol(3,4)P2 (PIP2) and phosphatidyl-inositol(3,4,5)P3 (PIP3)
in migrating cells, and was found to localize from the plasma membrane, directionally
away from the centrosome after nuclear polarization occurred (Wang et al., 2012).
Nuclear polarization was also reversed with the PI3K inhibitor, LY294002, and
nocodozole treatment.

Together, these studies provided evidence that microtubules

directly and indirectly stabilized the nucleus by the centrosome prior to the onset of
enucleation.
After the nucleus becomes polarized through microtubule-dependent processes, it
is extruded away from the centrosome. At this point, the cell is no longer rounded and
maintains a doublet morphology. Nuclear extrusion occurs through the formation of a
contractile actin ring (CAR) and a cleavage furrow at the point between the incipient
reticulocyte and pyrenocyte. Immunofluorescence experiments and time-lapse imaging of
enucleating erythroblasts revealed a phalloidin-positive focus between this junction (Ji et
al., 2008; Konstantinidis et al., 2012; ST and MC, 1989; Wang et al., 2012). Formation of
the CAR is driven by actin polymerization and is required for enucleation, as the actindepolymerizing

agent

cytochalasin

D

effectively

inhibited

nuclear

extrusion

(Konstantinidis et al., 2012; Ubukawa et al., 2012). Similar to the progression of mitosis
in other cells, the CAR is composed of actin filaments, and formation is driven by
RacGTPases (Ji et al., 2008). The final separation of the pyrenocyte and reticulocyte
7

occurs through a telophase-like abscission event. Lipid raft-containing vesicles deliver
membrane to the abscission point, mediated in part by clathrin. Knockdown or chemical
inhibition of clathrin mildly inhibited enucleation of primary human erythroblasts in vitro
(Keerthivasan et al., 2010).
Pinpointing the functions of a protein that acts both during terminal cell divisions
and enucleation can be limited because several events coordinated during enucleation
utilize generalized cytokinetic machinery. These issues are potentiated by differences
between in vitro primary cell culture systems and in vivo experimental mouse models.
For example, mDia2 is a formin and nucleates unbranched actin filaments. Initial
knockdown experiments in fetal liver erythroblast cultures suggested it specifically
functions to pomote erythroid nuclear extrusion (Ji et al., 2008). However, Watanabe et
al. showed that mDia2 function is highly intertwined with the prior cell divisions, as
mDia2 knockout mice have increased multinucleated erythroid progenitors (Watanabe et
al., 2013). Importantly, enucleation is the final step of erythroid development, and defects
in numerous critical processes upstream can result in impaired enucleation.

Cell cycle: regulation of RBC size and number
Regulation of the cell cycle is intimately correlated with the cell number and size
produced at the end of terminal differentiation. The earliest progenitors undergo
specialized cell divisions producing two daughter cells, each smaller in size than the
8

parental cell. The G1 phase is shortened and S phase becomes progressively shorter, both
allowing for decreased size after mitosis (Dolznig et al., 1995; Grebien et al., 2005).
Cyclin D3 and cyclin A2 promote the G1/S and G2/M transitions of the cell cycle,
respectively, and single nucleotide polymorphisms (SNPs) were identified by genomewide association studies (GWAS) to be associated with deviations in mean corpuscular
volume and RBC count (cyclin D3) and cell size (cyclin A2) (Ganesh et al., 2009;
Kamatani et al., 2010; van der Harst et al., 2012). Indeed, follow-up loss-of-function
studies validated roles for these cyclins in erythroid maturation in primary murine
erythroid culture systems (Ludwig et al., 2015; Sankaran et al., 2012). Erythroblasts
expressing cyclin D3-targeting shRNAs displayed fewer cell divisions during the
maturation process, resulting in larger and fewer resultant RBCs (Sankaran et al., 2012).
Meanwhile, cyclin A2 knockdown in fetal liver erythroblasts inhibited cell size by
regulating cytokinesis during the last cell division (Ludwig et al., 2015). In addition,
these studies support the idea that successful production of functional erythrocytes is
independent of abnormal cell size.
Perturbation of the specialized divisions during erythroid maturation is an
underlying cause of a rare condition called congenital dyserythropoietic anemia, wherein
the pathological hallmark of the disease is multinucleated erythroblasts in the bone
marrow. Causal mutations have been identified in CODANIN I (CDAN1) (Noy-Lotan et
al., 2009; Renella et al., 2011), SEC23B (Schwarz et al., 2009), and most recently
MKLP1 (KIF23) (Liljeholm et al., 2013). While all these genes are ubiquitously
9

expressed, the disease is largely erythroid-restricted, and studies of these mutations have
expanded our understanding of the cell divisions during terminal erythropoiesis. CDANI
remains a poorly understood protein that may facilitate histone assembly into chromatin,
and SEC23B encodes a protein involved in endoplasmic reticulum vesicle trafficking.
Meanwhile, MKLP1 is a well-studied kinesin-like motor protein part of the
centralspindlin complex, which organizes microtubules (Mishima et al., 2002), regulates
formation of the CAR (Pavicic-Kaltenbrunner et al., 2007), connects the central spindle
to the plasma membrane in preparation for abscission (Lekomtsev et al., 2012). How
mutations in these three ubiquitously expressed proteins are responsible for an erythroidrestricted disease is still unclear.

1.4 The Ubiquitin-proteasome system (UPS)
The UPS facilitates selective elimination of proteins, including those that are
irreversibly damaged, cytotoxic, or unnecessary. Three cooperating proteins coordinate
the ATP-dependent ubiquitination of the target protein. An E1 enzyme activates the 76amino acid polypeptide ubiquitin and transfers it to an E2 ubiquitin-conjugating enzyme.
E3 ubiquitin ligases mediate direct or indirect covalent linkage of ubiquitin monomers or
chains to substrates (Hershko et al., 1983). After the first ubiquitin is attached, ubiquitin
moieties are added to a lysine (K) reside of the previously attached ubiquitin: K6, K11,
K27, K29, K33, K48, or K63). K48-linked polyubiquitination classically, but not
exclusively, mediates recognition by the proteasome, a multi-subunit organelle that
10

includes numerous proteases (Thrower et al., 2000). However, it is now known that
ubiquitin attachments are post-translational modifications serving innumerable functions,
including cell cycle regulation, intracellular transport, cell signaling, and DNA repair
(Erpapazoglou et al., 2012; Spence et al., 1995; Xu et al., 2009).
While there are <10 E1 and ~40 E2 enzymes in cells, the diversity of E3 ubiquitin
ligases is much greater; over 600 are expressed (Li et al., 2008). Each recognizes a
limited repertoire of substrates and bestows specificity to the UPS. E3 enzymes are
categorized into two main families, depending on the presence of a HECT (Homologous
to E6-AP Carboxyl Terminus) or a RING (Really Interesting New Gene) domain. While
HECT-containing enzymes carry activated ubiquitin and directly ligate the group to
substrate, RING-containing enzymes act as scaffolds to bind the E2-ubiquitin enzyme
and substrate to indirectly mediate ubiquitination (Deshaies and Joazeiro, 2009).

The UPS in erythropoiesis
The system was initially described in reticulocytes (Ciechanover et al., 2012;
Etlinger and Goldberg, 1977; Wilkinson et al., 1980). Gene set enrichment analysis of the
global transcriptome of differentiating human erythroblasts revealed that UPS
components are highly enriched during late erythropoiesis (An et al., 2014; Egan et al.,
2015). In parallel, proteomics revealed that about 1/3 of known molecules of
ubiquitination pathways exist in the human RBC (Roux-Dalvai et al., 2008). Evidence of
11

the broad role of the UPS in erythropoiesis also stems from the use of small molecule
proteasome inhibitors. Studies using cultured erythroid cells demonstrated that exposure
to various proteasome inhibitors can dramatically inhibit erythroid differentiation and
maturation (Chen et al., 2002; Wölwer et al., 2015). A chemical screen on cultured,
maturing erythroblasts identified three proteasome-inhibiting compounds that inhibited
enucleation (Wölwer et al., 2015). One of these, bortezimib, is currently prescribed to
treat multiple myeloma, and an observed side effect of its use is anemia (San Miguel et
al., 2006). Despite having these clues, relatively few studies have elucidated substrates
recognized and assigned functions to UPS components during red blood cell formation.

Trim proteins
The Trim protein family consists of more than 70 members, defined by a tripartite
motif containing RING, B box, and coiled-coil (CC) domains (Marín, 2012). The
canonical amino acid motif in RING domains is two repeats of Cys-X-His-X2-Cys-X2Cys, where X is any amino acid (Freemont et al., 1991). The conserved cysteine and
histidine residues bind two atoms of zinc, maintain the overall protein structure, and form
a cleft on the surface of the RING domain, which supports binding of the E2 protein
(Deshaies and Joazeiro, 2009; Zheng et al., 2000).
The CC domain enables Trim protein oligomerization. The crystal structures of
the CC domains of TRIM5a, TRIM20, TRIM25, and TRIM69 all demonstrate that CC
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domains form interdigitating antiparallel hairpins, thereby positioning the RING domain
of one oligomer directly apposed with the C-terminal substrate-binding domain
(Goldstone et al., 2014; Li et al., 2014; Sanchez et al., 2014; Weinert et al., 2015).
Furthermore, several recent studies indicate that Trim protein multimerization is critical
for efficient enzymatic activity. Full-length TRIM25 and TRIM32 proteins successfully
formed dimers in solution and showed autoubiquitination activity, whereas truncated
mutant proteins lacking the CC domains were attenuated in both in vitro assays
(Koliopoulos et al., 2016; Streich et al., 2013). Catalytic activity of TRIM32 was partially
rescued by fusion of the RING domain to glutathione-S-transferase domain, which is
known to mediate dimerization (Streich et al., 2013).
Trim proteins have variable C-terminal domains that commonly mediate protein
interactions. More than half contain a C-terminal PRY-SPRY (Sp1a and Ryanodine
Receptor) domain (Reymond et al., 2001; Versteeg et al., 2013)2. Crystal structures of
other PRY-SPRY domains reveal six hypervariable immunoglobulin-like loops that
interact with substrate peptide (Biris et al., 2012; Woo et al., 2006) (D'Cruz et al., 2013)
(James et al., 2007). Of note, mutations in the PRY-SPRY domain of TRIM20, or
PYRIN, have been linked to an autoimmune disorder named Familial Mediterranean
Fever (Grütter et al., 2006; Weinert et al., 2015; Woo et al., 2006).
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1.5 β-globin gene regulation
As discussed in Section 1.3.1, terminally differentiating and maturing
erythroblasts utilize several mechanisms to dedicate a vast majority of cellular and
transcriptional machinery to produce hemoglobin.
Historically, scientists debated whether replacement of HbF by HbA was caused
by a switch in stem cell lineage between fetal development and adulthood. Does an RBC
expressing HbF have a different origin than an RBC expressing HbA? A series of clonal
analyses of primary erythroid progenitors revealed that erythroid colonies were
comprised of distinct populations of cells expressing HbA and cells expressing HbF
(Papayannopoulou et al., 1976; 1977). These studies not only indicated that adult and
fetal erythroid cells indeed share a common stem cell lineage, but also supported a model
where transcription network changes were responsible for hemoglobin switching. The
molecular mysteries of this transcriptional switch have spurred intense basic research
with the ultimate goal to discover new, targeted therapies for hemoglobinopathies.

The β-like globin genes
The five β-like globin genes lie on human chromosome 11 in the following order:
5’-ε-Gγ-Aγ-δ-β-3’ (Figure 1.2). ε is expressed during embryogenesis, Gγ and Aγ are
expressed during fetal development, and δ-globin and β-globin replace the fetal genes
within 6 months after birth. Upstream of the β-globin genes lies a cluster of five
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conserved DNase I hypersensitive sites (HSs), comprising the locus control region
(LCR). The HSs function as erythroid-specific enhancers and mediate high-level
induction of the β-like globin genes in maturing erythroid cells ((Forrester et al., 1986;
Kollias et al., 1986; Tuan et al., 1985), reviewed in (Li et al., 2002)). The absence of the
LCR dramatically reduces β-globin expression (Alami et al., 2000; Bender et al., 2000).
Lying 20-60 kb upstream of the β-globin genes, the LCR remotely activates gene
expression by chromosomal looping. When the embryonic genes are expressed during
primitive erythropoiesis, the LCR interacts with the embryonic globin genes and not the
adult globin genes. The LCR interactions with the gene promoters switch to temporally
coordinate the expression of the different globins (Carter et al., 2002; Tolhuis et al.,
2002).

Figure 1.2. Timing of
the β-like globin gene
switching

during

human development.
The

human

embryonic, fetal, and
adult globin chain relative expression levels are shown in blue, green, and red,
respectively. From (Sankaran and Weiss, 2015).
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Sickle cell disease
Sickle cell disease (SCD) was the first “molecular disease” and is caused by a
substitution of valine for glutamic acid, the 6th amino acid (D6V) (Pauling et al., 1949).
The mutant protein is incorporated into hemoglobin tetramers, which polymerize under
deoxygenating conditions and causes the RBCs to transform from a biconcave disk to a
sickle shape (HerrickIrons, 1910). Vaso-occlusive events are precipitated when the cells
enter smaller capillaries or the microvasculature and become deoxygenated, producing
elongated cells that obscure blood flow to the tissue. These complications include stroke,
pain, acute vascular necrosis, nephropathy, and ultimately premature mortality.

Rationale for HbF-inducing therapies
Studies of the interactions between HbS and other forms of hemoglobin has
provided the rationale for new therapies (Behe and Englander, 1979; Sunshine et al.,
1979). When mixed with HbS, HbA and HbF both significantly delayed and decreased
polymerization of HbS. However, HbF acts more potently. Compared to the
polymerization time of pure HbS, mixtures with 30% HbA have delayed polymerization
by 100-fold. However, when HbS is mixed with 30% HbF, polymerization is 104-fold
slower. Therefore, the biochemical effects of having 30% HbF tetramers are more
beneficial than observed the same ratio of HbA. In parallel, studying patients with sickle
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cell disease and varied diseased progressions have supported similar conclusions that
HbF expression alongside HbS is therapeutically beneficial. Baseline values of HbF
amongst sickle patients is variable, ranging from <5% to >30%. In the Cooperative Study
Sickle Cell Disease, HbF above 4% was associated with reduced painful crises (Platt et
al., 1991). A slightly greater increase in HbF level above 8.6% was associated with
decreased mortality (Platt et al., 1994). To date, this is the only known genetic modifier
of sickle cell disease death.
BCL11A
Bcl11a is a zinc-finger transcription factor historically known for its role in
lymphocyte and neural development. Because HbF expression and fraction of HbF+ cells
(F-cells) are quantitative traits, the dawn of modern genomics has opened the doors of
discovery. Genome-wide association studies elucidated the association between common
variants in the BCL11A locus on chromosome 2 with fetal hemoglobin levels (Menzel et
al., 2007; Uda et al., 2008). Knockdown of BCL11a in primary human erythroblasts cells
showed that it is a negative regulator of γ-globin expression (Sankaran et al., 2008a), and
erythroid-specific knockout mice inappropriately expressed γ-globin into adulthood (Xu
et al., 2011). Furthermore, co-inheritance of Bcl11a null alleles rescued the disease
manifestations of SCD in a humanized mouse model (Xu et al., 2011). Genetic studies
have identified rare occurrences of large genomic deletions including the BCL11A gene.
While these individuals have increased HbF expression, these deletions are also
associated with neurocognitive and developmental disorders (Basak et al., 2015; Funnell
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et al., 2015). Therefore, global or total-body inhibition of BCL11A by an ingested drug,
for instance, may have adverse effects on the brain.
More recently, Bauer et al. described an erythroid-specific enhancer of BCL11A
(Bauer et al., 2013). They used previous GWAS data to fine-map a region of intron 2 in
BCL11A. By matching the GWAS variants with DNase I hypersensitive sites found in
erythroid cells (but not in other cell types), three HS regions (+55, +58, and +62 kb from
the transcription start site) corresponded to SNPs linked to HbF variation. Deletion of the
enhancer in cell lines left the exonic sequence intact, but loss of the enhancer reduced
expression of BCL11A. The group further probed the 12-kb enhancer sequence to identify
the minimal region necessary for enhancer function by performing a saturating
CRISPR/Cas9 mutagenesis screen (Canver et al., 2015). Mutations induced by a single
gRNA targeting the +58 HS site upregulated γ-globin to the same level as deletion of the
entire enhancer. In parallel, Vierstra et al. screened eight zinc finger nuclease pairs
targeting the enhancer and found that the pair targeting within 20 nt of +58 was the most
effective at raising HbF expression (Vierstra et al., 2015). Both studies suggest that
enhancer activity, BCL11A expression, and subsequent HbF repression are dependent on
a single GATA1 motif at +58. The strong, safe effects of variation at this locus and target
resolution have made this locus the prime candidate for therapeutic genome editing.
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1.6 HPFH
Individuals heterozygous or homozygous for mutations that cause HbF expression
are asymptomatic. Usually identified incidentally by routine screening or because other
family members have a hematologic disorder, rare individuals have mutations in the βglobin gene cluster that cause hereditary persistence of fetal hemoglobin (HPFH). These
individuals have normal hemoglobin concentrations.
Several different models are currently thought to explain mechanisms of HbF
induction seen with HPFH. 1) Enhancer sequences are brought closer to HBG1 and
HBG2 (Forget, 1998); 2) removal of HBB and HBD eliminate competition with the LCR
(Akinsheye et al., 2011); and 3) regulatory sequences that play a role in γ-globin gene
repression are altered or created de novo (Wienert et al., 2015).

Deletional HPFH
Several deletions in the β-globin gene cluster result in HPFH. Heterozygotes have
reported greater than 30% HbF in a pancellular distribution, where all RBCs express
HbF. Homozygotes are clinically healthy but may have mild microcytosis (smaller
RBCs) and/or hypochromia (less hemoglobinization). The α-globin to γ-globin chain
synthesis can be mildly imbalanced, suggesting that γ-globin synthesis occurs at a lower
rate than the normal β-globin gene does. A schematic of the known deletions is shown in
Figure 1.2 (drawn based on references (Feingold and Forget, 1989; Henthorn et al., 1990;
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Huisman et al., 1971; Jagadeeswaran et al., 1982; Joly et al., 2009; Sankaran et al.,
2011)). HPFH-1 and HPFH-2 mutations are the most common and are large deletions
(>84 kb in length) and often encompass the HBB gene itself (Feingold and Forget, 1989).
These mutations genetically resemble and even overlap with those responsible for δβthalassemia. However, the mapping of these breakpoints highlighted a 3.5-kb region
within the β-globin gene cluster that is critical for γ-globin silencing (Sankaran et al.,
2011).

Figure 1.3. Map of known HPFH deletions in the β-globin gene cluster on
chromosome 11.
Vertical arrows indicate the HS sites of the LCR, boxes show the β-like genes, and
horizontal arrows denote the span of the deletions. Elements are drawn to scale.
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13-nucleotide HPFH deletion
Huisman et al. reported the smallest known HPFH deletion: a 13-nucleotide (nt)
mutation in the HBG1 promoter, 102 through 114 nt upstream of the transcriptional start
site (-102 to -114) (Gilman et al., 1988). The mutation was identified in two related
individuals with sickle cell trait and HbF levels of 31.8% and 30.1%. Aγ, encoded by
HBG1, represented over 80% of the γ-globin chains, suggesting that the mutation in the
promoter was responsible for the specific upregulation of Aγ−globin. Of note, three
additional point mutations lie in the same region, including a G-to-A change at -117 (117G>A, 10-20% HbF) (Berry et al., 1992; Collins et al., 1985), a C-to-T change at -114
(-114C>T, 11-14% HbF) (Fucharoen et al., 1990), and a G-to-T change at -109 (109G>T, 4.1% HbF) (Chassanidis et al., 2009). Transgenic mouse experiments served to
validate that these mutations were responsible for HPFH phenotypes. While a transgenic
mouse model is lacking for the 13-nt deletion, Ronchi et al. demonstrated that the -114
and -117 point mutations indeed induced γ-globin expression both in fetal liver and
peripheral blood of adult animals (Ronchi et al., 1996). This study also highlighted the
necessity for intact proximal elements upstream of -114. The γ-globin promoter
mutations provided the backbone for in vivo structure-function mapping and suggested
that these nucleotides are specifically important for hemoglobin switching.
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Chapter 2 Experimental Methods
Trim58 cloning
The full-length Trim58 gene, including 5’ and 3’ untranslated regions (UTR), was
initially TOPO cloned into pCRII-Dual vector (Invitrogen) from murine fetal liver
erythroblast

cDNA

using

the

following

primers

(Forward:

GCCATGGCCACGGCACCCGGGG, Reverse: CAGCACTTCTGGATGGGTTT). Full
length (wild type) Trim58 was subcloned from pCRII-Dual-Trim58 into retroviral vectors
using the following primers to create 5’ FLAG/HA epitope-tagged constructs (Forward:
GAAGATCTAGATCTGCCATGGACTACAAGGACGACGATGACAAATACCCATA
CGACGTCCCAGACTACGCTGCCTCAGCTCCTTCTGTG,
CGGAATTCCAGCACTTCTGGATGGGT).

The

RING-dead

Reverse:
Trim58

construct,

containing Cys>Ala missense mutations at residues 55 and 58 (within the RING domain),
was created from a full length Trim58 construct using a two-step PCR method using the
above full length Trim58 Forward and Reverse primers and the following mutationgenerating

primers

(Forward:

GGACCCCTGGCCTGGGGTGCGGCGTAGAC,

Reverse: GTCTACGCCGCACCCCAGGCCAGGGGTCC). The Trim58 PRY-SPRY
domain, including residues 281-485, was subcloned from a full length Trim58 construct
using

the

following

AGAAGATCTAGATCTGCCATGAGGGAGATG,

primers

(Forward:
Reverse:

CGGAATTCCAGCACTTCTGGATGGGT). This construct begins 8 amino acids
upstream and extends 25 amino acids downstream of the predicted PRY-SPRY domain.
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Live cell imaging plasmids were cloned into the BglII/EcoRI site of a pK1 vector
containing amino-terminal FLAG and carboxy-terminal mCherry tags (S. Kadauke & G.
Blobel, Children’s Hospital of Philadelphia) using the following primers (Forward:
GAAGATCTAGATCTATGGCCACGGCACCCG,

Reverse:

CCGGAATTCGAATTCGTATTCCTCACTTCTGGCAG). Trim58 ΔCC expressed in
E14.5 fetal liver cells as isolated by PCR from a murine fetal liver erythroblast cDNA
library.
Trim58 constructs were cloned into the BamHI/EcoRI or BglII/EcoRI sites in
several expression vectors for this study, including pCRII-Dual (Invitrogen), retroviral
MIGR1 (Murine Stem Cell Virus (MSCV) promoter-driven construct with downstream
IRES-GFP), retroviral pK1 (MSCV-driven construct with downstream IRES-puromycin),
and pGEX6P1 (GE Healthcare) for GST-tagged constructs.
Radioactive in situ hybridization
Embryonic day 14.5 (E14.5) murine embryos were fixed, dehydrated, paraffin-embedded,
sectioned, and stained with an antisense probe targeting Trim58 nucleotides 841-1455 per
protocols from the University of Pennsylvania Molecular Cardiology Research Center
Histology and Gene Expression Core Facility.
Flow cytometry
For fluorescence activated cell sorting of primary murine fetal liver erythroblasts,
single cell suspensions from whole fetal livers were stained with Ter119-APC
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(BioLegend) and CD71-PE (BD Pharmingen) for 45 min at 4 °C in PBS and sorted on a
FACSAria instrument (BD Biosciences) per a previously described gating strategy (Pop
et al., 2010).
For cultured murine fetal liver erythroblast analysis, 5x105 cells were stained
sequentially with 5 µM Hoescht33342 (Sigma) for 1 hr at 37 °C in fetal liver maturation
medium, Live/Dead near-IR fixable dead cell stain (Invitrogen) for 30 min at 4 °C in
PBS, and Ter119-PerCP-Cy5.5 and CD44-AF647 (BioLegend) for 45 min at 4 °C in PBS
with 2% fetal bovine serum (FBS). Cells were analyzed on an LSR Fortessa instrument
(BD Biosciences) maintained by the Flow Cytometry Core Laboratory of The Children’s
Hospital of Philadelphia Research Institute. Data were analyzed using FlowJo software
(TreeStar).
Quantitative real-time PCR
RNA was extracted using the RNeasy kit (Qiagen) with on-column DNAse
treatment. cDNA was prepared using the iScript cDNA kit (BioRad). Semiquantitative
real-time PCR was done using the standard curve method and SYBR green dye on a ViiA
7 real-time PCR system (Life Technologies). Real time primers used in this study probed
for murine Trim58 (Trim58; Forward: GAGCGTCTTTGGAACTTGTG, Reverse:
ACCCTCTGTGTTTCTCAAACTC),

dynein

TTGTACCGCATCCAAGAGAAG,

Reverse:

heavy

chain

(Dync1h1;

Forward:

GTTGTAGTCATTCACCGTTTCC),

dynein intermediate chain (Dync1i2, Forward: ACAGTCAAAGGCAGTAGCTG,
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Reverse:

CTGGTGTCCCTCAAACATCTC),

actin

(Actb;

Forward:

CCTTCCTTCTTGGGTATGGAATC, Reverse: AGCACTGTGTTGGCATAGAGGT),
hypoxanthine

guanine

phosphoribosyl

transferase

(Hprt;

Forward:

TCAGTCAACGGGGGACATAAA, Reverse: GGGGCTGTACTGCTTAACCAG), and
glyceraldehyde-3-phosphate
AGGTTGTCTCCTGCGACTTCA,

dehydrogenase
Reverse:

(Gapdh,

Forward:

CCAGGAAATGAGCTTGACAAA).

Target gene expression was normalized to the average of Actb, Gapdh, and Hprt values.
HBG1/2 and HBB mRNAs were quantified by SYBRGreen qPCR, as described (Deng et
al., 2014).
In silico analyses of Trim58 gene regulation and expression
ChIP-Seq data at the murine Trim58 locus were obtained from the Penn State
University

Bioinformatics

Genome

Browser

(https://mery.genome-

browser.bx.psu.edu/). The data presented in Figures 3.2C and 3.23 were generated
from primary fetal liver erythroblasts by ChIP-Sequencing and RNA-Sequencing,
respectively (Pimkin et al, in revision). Human TRIM58 mRNA tissue expression
patterns were obtained from publicly available microarray data (Figures 3.1A (Wu et al.,
2009) and 3.1B (Novershtern et al., 2011)). Erythroid TRIM58 expression data were
obtained from microarray analysis of FACS-purified human erythroblasts cultured from
peripheral blood buffy coat mononucleocytes (Figure 3.1C (Merryweather-Clarke et al.,
2011)).
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Murine fetal liver erythroblast isolation
E14.5 murine fetal livers were harvested from pregnant CD1 mice (Charles River
Laboratories), triturated, and passed through a cell strainer (BD Biosciences) to yield
stroma-free single cell suspensions. Erythroid progenitors were purified by negative
selection on magnetic beads using the EasySep Mouse Hematopoietic Progenitor Cell
Enrichment Kit (STEMCELL Technologies) according to the manufacturer’s
instructions, with the addition of biotin-conjugated anti-mCD71 (eBioscience).
Short hairpin RNA cloning
Short hairpin RNAs from pGIPZ vectors (Open Biosystems) were subcloned into
the “PIG” (MSCV-Puromycin-IRES-GFP) retroviral vector (Hemann et al., 2003). These
shRNA constructs are within a miR30 stem-loop structure to aid processing. Primers
(Forward:

AGATCTAGATCTTGCTGTTGACAGTGAGCG,

Reverse:

CTCGAGCTCGAGTCCGAGGCAGTAGGC) were used to clone the following shRNAs
into the MSCV-PIG vector BglII and XhoI sites. The sense strand is indicated in red,
antisense in blue, loop in green, and the common miR-30 context in black.
shLuciferase (RHS1705)
TGCTGTTGACAGTGAGCGCCCGCCTGAAGTCTCTGATTAATAGTGAAGCCAC
AGATGTATTAATCAGAGACTTCAGGCGGTTGCCTACTGCCTCGGA
shScrambled (RHS4346)
TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCAC
AGATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA
shTrim58 #3 (V3LMM_487333)
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TGCTGTTGACAGTGAGCGACCGAGACTCAGTGCTGAGAAATAGTGAAGCCAC
AGATGTATTTCTCAGCACTGAGTCTCGGCTGCCTACTGCCTCGGA
shTrim58 #4 (V3LMM_487334)
TGCTGTTGACAGTGAGCGCCTCCTTCTACAATGTCACAAATAGTGAAGCCAC
AGATGTATTTGTGACATTGTAGAAGGAGATGCCTACTGCCTCGGA
shTrim58 #5 (V3LMM_487335)
TGCTGTTGACAGTGAGCGCTTGGACTACGAAGCTGGTGAATAGTGAAGCCAC
AGATGTATTCACCAGCTTCGTAGTCCAAATGCCTACTGCCTCGGA
shTrim58 #7 (V3LMM_487337)
TGCTGTTGACAGTGAGCGCCGGGATCTTTTTGGACTACGATAGTGAAGCCAC
AGATGTATCGTAGTCCAAAAAGATCCCGATGCCTACTGCCTCGGA
Retroviral infection
Retroviral PIG constructs were packaged by co-transfection of pCL-Eco into 293T
cells via calcium phosphate transfection. To create retrovirus for human (HeLa) cell
infection, constructs were packaged by co-transfection of pVSVG and pCPG into 293T
cells. Retroviral supernatants were collected 24 and 48 hr post-transfection and kept at 80 oC until use. Cells were infected with retroviral supernatant containing 8 µg/mL
polybrene (Sigma) and 10 mM Hepes (Gibco) by centrifugation at 2800 rpm for 90 min
at 30 °C.
Fetal livery erythroblast culture conditions
Our methods were based on those initially devised by Zhang et al (Zhang et al., 2003)
with some modifications. Erythroid progenitors were “expanded” for 24-72 hrs in
StemPro-34 serum free media (Gibco) containing 10% SP34 supplement, 2 mM L27

glutamine (Gibco), 1% Penicillin/Streptomycin (Gibco), 0.1 mM 1-thioglycerol (Sigma),
1 µM dexamethasone (Sigma), 0.5 Units/mL Erythropoietin (Amgen), and 1% mSCFconditioned medium. At 18-24 hrs post-infection, puromycin (1 µg/mL) was added to
select for infected cells. Following expansion, cells were pelleted at 800 rpm for 3 min,
washed thrice in PBS, and cultured in fetal liver maturation medium (IMDM
(Mediatech/Cellgro), 10% BenchMark fetal bovine serum (Gemini Bioproducts), 10%
plasma derived serum (Animal Technologies), 5% Protein Free Hybridoma Media II
(Gibco), 2 mM L-glutamine (Gibco), 1% Pen/Strep (Gibco), 0.1 mM 1-thioglycerol
(Sigma), and 2 Units/mL Erythropoietin (Amgen)) for up to 48 hrs. After 48 hrs,
maturation was complete, cultures began to die, and analyses became unreliable.
Expansion and maturation cultures were kept below 1 million cells per mL at all times.
Erythroblast morphology analysis
Cells were centrifuged onto a glass slide and stained with May Grünwald-Giemsa
(Sigma). Light microscopy images were obtained with a Zeiss Axioskope 2 microscope,
Zeiss Axiocam camera, and Zeiss AxioVision 3.1 software (Carl Zeiss Microimaging) at
room temperature. Multinuclearity was assessed by visual inspection of May GrünwaldGiemsa-stained slides. The “Analyze Particles” feature within FIJI was used to quantify
nuclear sizes from slide images.
Western blot analysis
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Sample loading was normalized to protein content. Proteins were resolved on TrisGlycine gels (BioRad), transferred to 0.45 µm PVDF (Whatman) or Nitrocellulose
membrane (BioRad), and blocked in 5% milk. Primary antibodies included Dynein
Heavy Chain (R-325, Santa Cruz), Dynein Intermediate Chain (MAB #1618, Millipore),
Nup153 (QE5, Abcam), Gapdh (FL-335, Santa Cruz), α-globin (custom rabbit
polyclonal, Covance), Hemagglutinin (Y-11, Santa Cruz), FLAG (M2, Sigma), Codanin1
(G-1, Santa Cruz), and β actin-HRP (Sigma). Anti-Trim58 antibodies were raised against
a peptide from the N-terminus (ERLQEEARCSVCLDFLQEPISVD) of murine Trim58
(Thermo Scientific). HRP-conjugated anti-mouse and anti-rabbit secondary antibodies,
protein size markers, and other reagents were from Thermo Scientific.
Hemoglobin content quantification
Hemoglobin content in mature erythroblast cultures was quantified by Drabkin’s
assay as described (Campbell et al., 2013). Culture pellets were imaged in 1.1 mL FACS
tubes (VWR) with an iPhone 4.
Immunoprecipitation assays
For all immunoprecipitation (IP) experiments, cells were lysed in buffer
containing 10 mM Tris (pH 7.4), 150 mM sodium chloride, 0.5% NP-40 (Sigma), 1 mM
EDTA (pH 8.0), 10 µM proteasome inhibitor (MG132, Enzo), and 1:500 protease
inhibitor cocktail (Sigma). For FLAG- PS immunoprecipitation, 400 million FACSpurified GFP+ G1E cells, cultured as described (Weiss et al., 1997), were lysed,
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precleared with a 1:1 mix of Protein A and rProtein G agarose (Invitrogen), and
incubated overnight with EZView Red Anti-Flag M2 Affinity Gel (Sigma) at 4 oC. After
washing thrice with IP buffer, immunoprecipitated material was eluted off of beads with
100 µg/mL 3X FLAG peptide (Sigma) at 4 °C for 1 hr with intermittent agitation and
used for further analyses.
For DIC immunoprecipitation, precleared lysate from 15 freshly isolated whole E14.5
murine fetal livers (~300 million cells) were incubated with anti-DIC antibody (Millipore
MAB #1618) overnight. rProtein G agarose beads (Invitrogen) were then added for 4 hrs
at 4 °C. Beads containing immunoprecipitated material were washed thrice in IP buffer,
boiled in 2X Laemmli Sample Buffer (Sigma), and analyzed immediately.
Mass spectrometry
Immunoprecipitates were size-fractionated by SDS-PAGE (4-15% gradient gel,
BioRad) and stained with Coomassie Blue Silver overnight. Following washing in
deionized water, the indicated bands were manually extracted, digested with trypsin, and
subjected to liquid chromatography and nanospray/linear trap quadrupole mass
spectrometry using a ThermoFinnigan LTQ linear ion trap mass spectrometer at the
University of Pennsylvania Proteomics Core Facility. Data were analyzed via Sequest
and Scaffold3 software packages. Presented data represent unweighted spectral counts,
unique peptide counts, and percent protein coverage for proteins identified by ≥2 peptides
with >99% protein/>95% peptide confidence.
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In vitro GST pull down assays
For the in vitro binding experiments shown in Figures 3.10A and 3.10B, GST and
GST-PS proteins were prepared in previously described conditions (Kihm et al., 2002). E.
coli BL21 cells were grown at 37 °C for 3 hrs and induced to express protein by addition
of 0.1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 3 hrs at 30 °C. Cell pellets
were resuspended in BC500 buffer (10 mM Tris-HCl (pH 8.0), 500 mM KCl, 20%
glycerol, 1% NP-40, 0.5 mM EDTA, 1 mM DTT, 0.5 mg/mL lysozyme, 0.05 mg/mL
DNAse I, and protease inhibitor cocktail (Sigma)) and sonicated. Lysates were clarified
by centrifugation at 10,000 rpm for 10 min at 4 °C. Cleared lysates were incubated with
washed glutathione-Sepharose beads (GE Health Sciences) overnight at 4 °C, washed
thrice in BC500, and eluted off of beads with 20 mM reduced glutathione solution
containing 50 mM Tris-HCl (pH 8.8), 100 mM NaCl, 1 mM DTT, and protease inhibitor
cocktail (Sigma).
Bovine brain holodynein was purified as described (Bingham et al., 1998). pCMVbased HA-tagged portions of human dynein intermediate chain (generously donated by
K. Kevin Pfister, University of Virginia) were introduced into 293T cells by calcium
phosphate transfection. Transfected 293T cells expressing HA-tagged DIC constructs
were lysed in pull down (PD) Buffer (20 mM Tris pH 7.4, 150 mM potassium chloride, 1
mg/mL BSA, 1:500 protease inhibitor cocktail (Sigma)) 24 hrs after transfection.
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For pull down assays, recombinant GST or GST-PS (1 µmol at 4 mM final
concentration) was incubated with substrate (5 µg holodynein (~4 fmol at 16 nM final
concentration) or 400 µg 293T lysate containing DIC truncation) and 20 µL glutathioneSepharose beads (GE Healthcare) in PD Buffer for 2 hrs at 4 °C with rotation. All pipette
tips and Eppendorf tubes were passivized with 1 mg/mL bovine serum albumin (Sigma)
prior to use. Beads were subsequently pelleted, washed thrice with PD Buffer, boiled in
2X Laemmli Sample Buffer (Sigma), and analyzed.
SEC-MALLS experiments
Our collaborators, Drs. Joel Mackay and Ana Silva, of the School of Molecular
Bioscience at the University of Sydney, Australia, conducted these experiments. Trim58
PS (residues 281-485) and dynein intermediate chain (residues 1-120) were expressed
separately in E. coli Rosetta 2 (DE3) cells at 25 °C for 16 hrs. Cell pellets were
resuspended in 50 mM sodium phosphate (pH 7.5) and 0.5 M sodium chloride for GSTPS, or 50 mM CHES pH 10 and 1 M sodium chloride for GST-DIC(1-120). Cells were
lysed by sonication following the addition of 1 mg/mL lysozyme, 1 mM DTT, 1 mM
PMSF, 0.05 mg/mL DNAse I, 0.05 mg/mL RNAse A and Complete EDTA-free protease
inhibitors (Roche). Cell lysates were incubated with glutathione-Sepharose resin
(Novagen) for 1 hr at 4 °C and washed. GST-DIC(1-120) was eluted using 30 mM
glutathione, whereas PS was cleaved from the GST tag with HRV-3C protease overnight
at 4 °C. Both proteins were then purified by size exclusion chromatography, using a
Superdex 75 HiLoad 16/600 column. PS was eluted in 20 mM sodium phosphate (pH
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7.5) and 50 mM sodium chloride, and GST-DIC(1-120) in 20 mM CHES pH 10 and 100
mM sodium chloride.
Purified PS (200 µL at 3.3 µM) and GST-DIC(1-120) (200 µL at 16.4 µM) were
run separately on a Superdex 200 10/300 GL column connected to a MiniDawn Treos
(Wyatt Technology). A mixture of PS and GST-DIC (200 µL of a mixture of PS at 13.2
µM and GST-DIC at 16.4 µM) was incubated for 1 hr at room temperature and then
eluted on the same SEC-MALLS setup. All samples were eluted in 20 mM Tris pH 8 and
100 mM sodium chloride at 0.5 mL/min. Molecular masses were calculated using a dn/dc
value of 0.185 mL/g.
Immunofluorescence assay sample preparation
HeLa cells were transiently transfected on 12 mm coverslips (VWR) with pK1based Trim58 constructs or pEGFP-based mCherry-CC1 (human), using Lipofectamine
2000 reagent (Invitrogen) per the manufacturer’s instructions. After 36 hrs, cells were
fixed in 4% paraformaldehyde for 5 min, permeabilized in 0.1% Triton-X 100 for 5 min,
and blocked in PBS containing 3% FBS for 1 hr at room temperature. Transfected HeLa
cells were stained with GM130 (BD Biosciences) overnight at 4 °C, and then with goat
anti-mouse Alexa Fluor 488 (Invitrogen) for 1 hr at room temperature. Cells were
mounted on glass slides with Prolong Gold Antifade Reagent with DAPI (Invitrogen).
For erythroblast immunofluorescence assays, cells were layered onto glass slides
previously treated with Vectabond reagent (Vector Laboratories) and incubated for 10
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min at 37 °C. Erythroblasts were fixed and permeabilized as described above, stained
with Alexa Fluor 488-conjugated anti-aTubulin (Millipore) overnight at 4 °C, and
mounted.
Time lapse microscopy
HeLa cell lines were plated on a FluoroDish (World Precision Instruments, 0.17 mmthick glass bottom) in DMEM (Gibco) containing 10% FBS and 1% sodium pyruvate at a
concentration of 250,000-500,000 cells per mL. Beginning 24-36 hrs later, cells were
imaged at 5 min intervals for 12 hrs in an environmental chamber at 37 °C and 5%
carbon dioxide. Time lapse and static erythroblast imaging were performed on an
Olympus IX70 inverted microscope with a Photometrics CoolSnap HQ high-resolution
CCD camera. Images were acquired and processed using Deltavision Softworx software.
Static HeLa cell imaging was performed on a Zeiss LSM 710 Confocal microscope with
ZEN 2011 acquisition software. The University of Pennsylvania Perelman School of
Medicine Cell and Developmental Biology Microscopy Core maintained these
microscopes. Images were analyzed using FIJI (Schindelin et al., 2012) and Volocity
Software (PerkinElmer).
Animals
An 18.8-kb region including part of the murine Trim58 gene locus was retrieved
from Bacterial Artificial Chromosome (BAC) bMQ116f01 (Children’s Hospital Oakland
Research Institute, CHORI) and subsequently cloned into recombineering vectors using
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materials obtained from the National Cancer Institute Biological Resources Branch.
Artificial loxP sites were inserted to flank exon 3, and Cre recombinase was transiently
expressed in E.coli to excise exon 3. This purified construct constituted the Trim58 exon
3 deletion targeting cassette. The Trim58 gene was disrupted in Sv129 embryonic stem
(ES) cells by transient expression of the targeting cassette and subsequent recombination
into the intact genomic locus. ES cells were analyzed via Southern blot for the expected
pattern after StuI restriction enzyme digestion. A single ES cell clone was injected into
FVB murine blastocysts, and chimeric offspring were crossed with FVB mice. A PCRbased strategy was used to genotype these mice for Trim58. The mice used to generate
data in this study were subsequently backcrossed at least 4 generations on a C57Bl/6
background for additional analysis. The Children’s Hospital of Philadelphia and St. Jude
Children’s Research Hospital Institutional Animal Care and Use Committees approved
all animal protocols.
Peripheral blood and tissue analysis
Peripheral blood was collected in EDTA-coated tubes via retro-orbital sinus or
tail vein. Complete blood counts were determined using the Hemavet 950 (Drew
Scientific). For phlebotomy studies, 200 µL of blood were collected on days 0 and 2, and
fluid volume was replaced with intraperitoneal injection of sterile saline. For peripheral
blood analysis of entire blood volume, cardiac puncture was performed under anesthesia.
Blood was washed once with PBS, and layered onto a Percoll/NaCl density gradient
(1.096-1.058 g/mL) and centrifuged at 250g for 30 min. Purified reticulocytes
35

populations were validated by flow cytometry using thiazole orange Retic-Count stain
(BD).
For phenylhydrazine treatment, 50mg/kg 1-acetyl-2-phenylhydrazine (Sigma) was
injected intraperitoneally on two consecutive days. Serial hematocrit levels were
determined by standard methods after removing 20 µL of blood from the tail.
Purification of Ter119+ erythroid cells
Fetal liver and bone marrow erythroblasts were purified by magnetic sorting using
the STEM CELL reagents for PE positive selection with Ter119-PE antibody.
Effect sizes of mouse and human TRIM58 alleles
We used the student t-test to calculate the effect sizes of RBC number and MCV
in Trim58-/- versus Trim58+/+ mice. We used beta values (β) from GWAS-reported
variants associated with the same traits to determine the effect sizes (rs38111444 for
RBC number and rs11204538 for MCV)(Kamatani et al., 2010; van der Harst et al.,
2012). Beta values (β) were converted to Cohen’s D effect sizes using the following
formula: Cohen’s D = β/sd(β), where sd(β) = sqrt(N/se(β)).

gRNAs and Constructs
gRNA-1: GCTTGTCAAGGCTATTGGTCA
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gRNA-2: GTGTCAAGGCTATTGGTCAAG

gRNA

sequences

were

selected

using

a

CRISPR

design

tool

(www.crispr.mit.edu), generated as oligonucleotides, and cloned into plasmids using
BbsI. The all-in-one expression plasmid spCas9(BB)-2A-GFP (PX458) was a gift from
Feng Zhang (Addgene plasmid #48138). AIO-mCherry vector was cloned by replacing
T2A-GFP with IRES-mCherry. The lentiCRISPRv2 was a gift from Feng Zhang
(Addgene plasmid #52961). Lentiviral CRISPR-GFP and –mCherry plasmids used in this
study were generated by replacing the puromycin resistance gene with IRES-GFP or
IRES-mCherry.
Erythroid differentiation of human peripheral blood CD34+ cells
Circulating G-CSF-mobilized human CD34+ cells were obtained from two
deidentified healthy donors (Key Biologics, Lifeblood) and enriched by immunomagnetic
bead selection using an AutoMACS instrument (Miltenyi Biotec).
CD34+ cells were cultured in a three-phase erythroid differentiation protocol
consisting of IMDM (Gibco) supplemented with 2% human AB plasma, 3% human AB
serum, 1% penicillin/streptomycin, 3 units/mL heparin, 10 µg/mL insulin, and 3 units/mL
erythropoietin (EPO) (Amgen). Phase I (days 1-7) also included 200 µg/mL HoloTransferrin (Sigma-Aldrich), 10 ng/mL stem cell factor (SCF) (PeproTech, Inc.) and 1
ng/mL IL-3 (PeproTech, Inc.). Phase II (days 8-12) included the same cytokines, except
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that IL-3 was withdrawn. During phase III (days 13 and beyond) Holo-Transferrin was
increased to 1 mg/mL, and SCF was removed. Erythroid differentiation and maturation
were monitored by flow cytometry using anti-CD71-PE (BD Biosciences, clone MA712), anti-CD235-FITC (BD Biosciences, clone GA-R2), anti-Band3-APC (gift from
Xiuli An, NY Blood Center), anti-α4-integrin-VioBlue (Miltenyi, clone MZ18-24A9).
HUDEP Cell culture
HUDEP clone 2 (HUDEP-2) cells were cultured as previously described. Cells
were expanded in StemSpan SFEM (Stem Cell Technologies) supplemented with 1 µM
dexamethasone, 1 µg/mL doxycycline, 50 ng/mL human SCF, 3 units/mL EPO, and 1%
penicillin/streptomycin. HUDEP-2 cells were differentiated in the Phase III medium used
for CD34+ erythroid cultures. These cells tested negative for mycoplasma.
Generation of genomic deletions
CD34+ cells were transduced by centrifuging with lentivirus (multiplicity of
infection 40) at 2,800 rpm, 37°C for 90 min with 8 µg/mL polybrene in Phase I erythroid
differentiation medium (CD34+) cells or HUDEP-2 expansion medium (for HUDEP-2
cells). The cells were incubated overnight with virus and were switched to fresh medium
the following morning. For transient editing, the Amaxa 2b (Lonza; program U-008) was
used to electroporate 1-5 million CD34+ or HUDEP-2 cells with DNA plasmid containing
gRNA, Cas9, and GFP (2 or 10 µg).
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To generate edited HUDEP-2 clones, cells were electroporated with 10 µg DNA
plasmid encoding gRNA-1, Cas9, and GFP. Single GFP+ cells were then sorted into 96well plates after 24 hours and expanded for 14-21 days. Genomic DNA was isolated
using a DNA extraction buffer (100 mM Tris HCl, pH 8.3; 200 mM NaCl; 5 mM EDTA;
1% Triton X-100; 200 µg/mL) proteinase K) followed by incubation at 50°C for 1 hour,
then 85°C for 30 minutes.
HbF protein analysis
Erythroid cells derived from CD34+ cells were fixed with 0.05% glutaraldehyde
and permeabilized with 0.1% TritonX-100. Cells were stained with anti-HbF-APC
antibody (Invitrogen, HBF-1 clone) and analyzed by flow cytometry. HPLC
quantification of HbF was performed using a cation-exchange column (Primus
Diagnostics).
In vitro sickling assay
Human SCD CD34+ HSPCs (genotype HbSS) were purified from deidentified,
discarded whole blood from partial exchange RBC transfusions (considered “not human
subject research” by the St. Jude Children’s Hospital Institutional Review Board),
differentiated into erythroblasts and cultured in 2% oxygen levels between days 14 and
17 of culture (de Vasconcellos et al., 2014). Phase contrast microscopy (CKX41
microscope, Olympus) was performed within 10 minutes of exposure to atmospheric
oxygen and analyzed by manual counting of sickled cells, with blinding to sample
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genotype. The cell permeable nuclear stain Hoechst 33342 (Sigma) was used to quantify
nucleated cells by flow cytometry.
Methylcellulose colony assays
Human CD34+ cells were electroporated with GFP, Cas9 and gRNA expression
plasmid using an Amaxa Nucleofector 2b (Lonza), program U-008 and cultured for 24
hours. Live GFP+ cells were purified by fluorescent activated cell sorting (FACS) for
GFP expression and seeded at 300 cells/ml into cytokine-free human methylcellulose
(Stemcell) (300 cells/3 cm dish) supplemented with 2 U/mL EPO, 10 ng/mL SCF, 1
ng/mL IL-3, and 1% penicillin/streptomycin. Individual BFU-E colonies were picked
after two weeks of culture.
Deep sequencing of genome modifications
DNA was extracted from cells using Blood and Tissue DNA Extraction Kits
(Qiagen). PCR amplification using CloneAmp HiFi Premix was performed with primers
including Nextera adapters. An additional PCR was performed to individually index each
sample, followed by sequencing on a MiSeq platform (Illumina) with 250bp, paired-end
reads. The sequence alignment and mutation detection were performed using CLC
Genomics Workbench (CLC Bio). HBG1/2 PCR primers used are as follows:
HBG1-specific Fwd: CGCTGAAACTGTGGTCTTTATGAAAATT
HBG2-specific Fwd: GCACTGAAACTGTTGCTTTATAGGAT
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HBG common Rev1 (with HBG-specific Fwd): GGCGTCTGGACTAGGAGCTTATTG
HBG-nonspecific Fwd: ATAACCTCAGACGTTCCAGAAGCGAGTGTG
HBG common Rev2 (with HBG-nonspecific Fwd):
AGAAGTCCTGGTATCCTCTATGATGGGAG

qPCR detection of 5.2-kb deletion alleles
A primer and probe set was designed to detect amplification of a HBG1 promoterspecific sequence. TaqMan qPCR was performed on genomic DNA samples from
HUDEP-2 and CD34+ cells using Universal TaqMan Mix (Thermo Fisher Scientific) for
quantification of triplicates for each sample. ΔΔCt values were calculated based on
amplification of RNaseP (Thermo Fisher Scientific) for copy number reference.
5.2kb Fwd: ACGGATAAGTAGATATTGAGGTAAGC
5.2kb Rev: GTCTCTTTCAGTTAGCAGTGG
Taqman probe (FAM): ACTGCGCTGAAACTGTGGTCTTTATGA
Fluorescence in situ hybridization (FISH)
A 5.2-kb probe encompassing the intervening region between gRNA-1 cleavage
sites in HBG2 and HBG1 was generated by PCR amplification and cloned using TA
vector (Promega). Nick translation was used to label purified DNA with red-dUTP
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(Alexa-Fluor-594, Molecular Probes), and a control HBB probe (RP11-1205H24)
independently with green-dUTP (Alexa-Fluor-488, Molecular Probes). The probes were
hybridized simultaneously with interphase and metaphase cells in 50% formamide, 10%
dextran sulfate, and 2× SCC. Metaphase cells were stained with DAPI and scored for
signals representing the potentially deleted region (red) and HBB (green).
Statistical analyses
Pairwise comparisons were assessed using an unpaired two-tailed Student's t-test.
Results were considered significant when P - value < 0.05. Linear regression analysis
was performed assess potential correlation between BFU-E colony mutation frequencies
and γ-globin ratio. Tests were performed and graphed using Prism software (GraphPad).
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Chapter 3 The role of Trim58 in erythropoiesis

We initially became interested in studying Trim58 because of its identification by
genome-wide association studies (GWAS) as a protein that potentially regulated human
erythrocyte traits. GWAS do not distinguish causal variants from blocks of SNPs in
linkage disequilibrium, however, so follow-up studies were required to test whether
TRIM58 variation was responsible for changes in RBC formation and function.
Moreover, Weiss lab alum Eugene Khandros, M.D., Ph.D., found that Trim58 coimmunoprecipitated with protein aggresomes containing insoluble α-globin. Together,
these forward genetic and biochemical screens suggested that Trim58 contributed to
erythropoiesis and potentially in the setting of disease. In this work, we identified Trim58
as an erythroid-specific E3 ubiquitin ligase with induced expression during late
erythropoiesis. We performed short hairpin (sh) RNA-mediated knockdown studies in
primary fetal liver erythroblasts to investigate its role in terminal maturation and
enucleation. These studies were performed with Christopher Thom, M.D., Ph.D. and
were published in Developmental Cell (2014). Figures and Tables can be found at the end
of the text.
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Introduction
Humans produce about 2 million red blood cells each second to replace those lost
by senescence (McGrath and Palis, 2008) in a process termed erythropoiesis. Mature red
blood cells (erythrocytes) contain high levels of the O2 carrier hemoglobin and are
distensible enough to withstand repeated passages through narrow capillary beds. These
properties are acquired during precursor maturation through specialized cell divisions
associated with activation of erythroid specific genes (Cheng et al., 2009; Welch et al.,
2004), repression of alternate lineage genes (Cheng et al., 2009; Kingsley et al., 2013;
Welch et al., 2004), global DNA demethylation (Shearstone et al., 2011), reduced cell
volume (Dolznig et al., 1995) and ejection of the nucleus to yield a reticulocyte, which
develops further into a mature red blood cell (Liu et al., 2010). The mechanisms that
govern these changes in cell structure and morphology are incompletely understood.
The process of nuclear expulsion from erythroblasts (Keerthivasan et al., 2011;
Konstantinidis et al., 2012) occurs exclusively in mammals and may represent an
evolutionary adaptation to optimize erythrocyte rheology for transport through small
capillary beds (Gaehtgens et al., 1981a; Mueller et al., 2008). Erythroblast enucleation is
preceded by nuclear condensation and requires histone deacetylation (Ji et al., 2010;
Popova et al., 2009) and suppression of the Myc proto-oncogene (Jayapal et al., 2010).
The condensed nucleus polarizes to one side of the cell via transport mechanisms that
require microtubules and phosphoinositide 3-kinase (Wang et al., 2012), followed by Rac
GTPase-mediated formation of a contractile actomyosin ring between the incipient
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reticulocyte and nucleus (Ji et al., 2008; Konstantinidis et al., 2012). Forces generated by
the contractile ring promote further nuclear extrusion (Ji et al., 2008; Wang et al., 2012).
Final separation between the reticulocyte and nucleus is facilitated by transport of lipid
vesicles to the interface, which facilitates remodeling and resolution of the plasma
membrane surrounding both structures (Keerthivasan et al., 2010; 2011). The ejected
nucleus with surrounding plasma membrane is termed a pyrenocyte (McGrath and Palis,
2008). In vivo, free pyrenocytes are scavenged by macrophages (Soni et al., 2006), while
reticulocytes are released into the circulation and undergo further maturation (Gifford et
al., 2006). This process shares several features with cytokinesis (Keerthivasan et al.,
2010; Konstantinidis et al., 2012). Moreover, all of the proteins currently known to
participate in erythroblast enucleation are ubiquitously expressed and most function in
mitosis. How erythroblasts co-opt generalized mitotic machinery for the lineage specific
process of enucleation is unknown. Presumably, this is mediated in part by the expression
of one or more erythroid restricted proteins.
Here, we identify a role for the erythroid protein Trim58 in erythroblast
enucleation. Trim58 is a member of the tripartite motif-containing family of proteins,
whose members function as E3 ubiquitin ligases broadly in physiology and disease
(Napolitano and Meroni, 2012). Genome-wide association studies (GWAS) show that
single nucleotide polymorphisms (SNPs) linked to the human TRIM58 gene associate
with variations in the size and/or number of circulating erythrocytes (Kamatani et al.,
2010; van der Harst et al., 2012). Here we identify Trim58 as an erythroid restricted
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protein that facilitates erythroblast enucleation. Mechanistic studies suggest that Trim58
exerts this function by inducing degradation of the microtubule motor dynein. These
findings are the first to identify an erythroid specific protein that participates in
erythroblast enucleation, likely by targeting a ubiquitous protein complex that is essential
for normal function in virtually all other eukaryotic cells.
Results

Trim58 is induced during late stage erythropoiesis
High-level human TRIM58 expression is specific to the erythroid lineage (Figures
3.1A and 3.1B) and is strongly induced during the late stages of maturation (Figure
3.1C). In situ hybridization analysis of embryonic day 14.5 (E14.5) mouse embryos
showed predominant Trim58 mRNA expression in the fetal liver, an erythropoietic tissue
(Figure 3.2A). Semiquantitative real-time PCR showed that Trim58 mRNA is
upregulated >100-fold in late stage murine fetal liver erythroid precursors (Figure 3.2B).
Chromatin immunoprecipitation-sequencing (ChIP-Seq) of primary erythroblasts
demonstrated that the essential erythroid transcription factors Gata1 and SCL/Tal1 bind
the Trim58 locus within the first intron, a common location for erythroid specific
enhancers (Figure 3.2C) (Cheng et al., 2009; Pimkin et al., 2014). Thus, the Trim58 gene
is strongly and specifically induced during terminal erythroid maturation, in part via
direct activation by key hematopoietic transcription factors.
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Trim58 regulates erythroblast enucleation
We used shRNAs to suppress Trim58 expression during the in vitro maturation of
primary fetal liver erythroblasts (Zhang et al., 2003). We infected purified E14.5 murine
fetal liver erythroid precursors with retroviruses encoding Trim58-directed or control
shRNAs along with a puromycin resistance cassette and green fluorescent protein (GFP)
(Figure 3.3A) (Hemann et al., 2003). Infected cells were cultured for 1-3 days with
dexamethasone, stem cell factor (SCF), erythropoietin (Epo) and puromycin to promote
immature erythroblast expansion and select for infected cells. The erythroblasts were then
switched to medium containing Epo only, which induced maturation to the reticulocyte
stage. Four different shRNAs reduced Trim58 mRNA and protein by 60-90% (Figures
3.3B and 3.3C). During late erythroid maturation, erythroblasts expel their nuclei to
become anucleate reticulocytes that are Hoechst-negative by flow cytometry (Figure
3.4A). The kinetics of enucleation were delayed in Trim58-deficient cultures (Figure
3.4B), and enucleation was consistently inhibited at 48 hrs maturation by all four Trim58directed shRNAs analyzed compared to controls (Figures 3.4C). Histological staining
confirmed these findings, showing reduced proportions of reticulocytes in Trim58deficient cultures (Figures 3.4D and 3.4E). Trim58 suppression also increased the
proportions of mature erythroblasts containing two or more nuclei (Figure 3.5).
Several parameters of erythroid maturation were not altered by Trim58
knockdown, including downregulation of the cell surface marker CD44 (Figure 3.6)
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(Chen et al., 2009). Trim58 knockdown produced only small and inconsistent effects on
erythroblast proliferation (Figure 3.7A) and viability (Figure 3.7B). Hemoglobin
accumulation (Figure 3.8A) and nuclear condensation (Figure 3.8B) occurred normally
after Trim58 knockdown. Overall, these findings demonstrate that Trim58 depletion
caused selective defects during late stage erythropoiesis, including reduced enucleation
and also increased formation of multinucleated cells.

Trim58 binds the molecular motor dynein
Trim58 is predicted to be an E3 ubiquitin ligase with characteristic functional
modules, including a PRY-SPRY (PS) domain that mediates substrate interactions
(Figure 3.9A) (James et al., 2007; Woo et al., 2006). We performed pull down studies to
identify Trim58 protein-binding partners, including potential degradation substrates. We
used the isolated PS domain for these studies because ectopic expression of full-length
wild type (WT) Trim58 was toxic to erythroblasts (data not shown). We expressed FLAG
epitope-tagged PS domain in the erythroblast cell line G1E (Weiss et al., 1997), which
contains no endogenous Trim58 protein, immunoprecipitated (IP) with FLAG antibody
and analyzed the recovered proteins by SDS-polyacrylamide gel electrophoresis. This
analysis identified five discrete protein bands (Figure 3.9B). Mass spectrometry of these
bands identified multiple subunits of the cytoplasmic microtubule motor protein complex
dynein (Table 3.1), as well as nuclear pore complex proteins, a Golgi component, and
several other proteins (Table 3.2). Dynein regulates nuclear positioning and microtubule
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structure within cells (McKenney et al., 2010; Splinter et al., 2010) and it was already
known that erythroblast enucleation is microtubule-dependent (Konstantinidis et al.,
2012; Wang et al., 2012). Therefore, to investigate further a potential role for Trim58 in
erythroblast enucleation, we focused on its interactions with dynein.
We confirmed the Trim58-dynein interaction in G1E cells by FLAG-IP followed
by Western blotting for dynein intermediate chain (DIC) and dynein heavy chain (DHC)
(Figure 3.9C). Immunoprecipitation of DIC from mouse fetal liver recovered Trim58,
demonstrating an interaction between the endogenous proteins (Figure 3.9D). In vitro
pull down assays showed that recombinant GST-tagged PS interacted with purified
holodynein, indicating a direct and specific interaction (Figure 3.10A). Dynein is a multisubunit complex that includes DHC, DIC, light intermediate chains, and light chains. The
DIC mediates dynein interactions with several accessory proteins, mainly via the amino
terminus (McKenney et al., 2011; Vallee et al., 2012). To test whether Trim58 interacted
with DIC, we expressed hemagglutinin (HA)-tagged segments of the DIC amino terminus
in 293T cells, incubated lysates with GST proteins and glutathione-Sepharose beads, and
analyzed interacting polypeptides (Figure 3.10B). Western blotting for HA showed that
PS interacted with DIC through an interface within the first 73 amino acids. We then used
size-exclusion chromatography coupled to multiangle laser light scattering (SECMALLS) to confirm this interaction in vitro using purified PS and DIC (residues 1-120).
Bacterially expressed PS and GST-DIC(1-120) each eluted in gel filtration as a single
peak when run individually (Figure 3.10C). MALLS data, which provide a reference-free
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estimate of solution molecular weight, showed that PS eluted as a monomer (observed
MW = 25.6 kD; expected mass = 23.3 kD), whereas GST-DIC(1-120) ran as a dimer
(observed MW = 91.2 kD; expected mass of dimer = 79.6 kD), as a result of the known
dimerization of GST (Fabrini et al., 2009). A ~1:1 mixture of the two proteins also eluted
predominantly as a single peak with a lower retention time, as expected for the formation
of a complex. The molecular weight of this signal calculated from MALLS data (126.2
kD) is consistent with a 2:2 complex (expected mass = 114.4 kD) that represented a 1:1
Trim58-DIC complex that additionally dimerized through the GST moiety. Together,
these data show that Trim58 binds dynein directly through physical interactions between
its PS domain and the DIC amino-terminus (Figure 3.10D). This region of DIC contains a
coiled coil domain that interacts with other dynein regulatory proteins, including the
dynactin subunit p150Glued and NudE (Ma et al., 1999; McKenney et al., 2011).

Trim58 promotes dynein degradation
Next, we expressed FLAG/mCherry-tagged full length WT Trim58 in HeLa cells,
which do not express endogenous Trim58, and assessed the effects on dynein protein
levels. As controls, we expressed vector alone (V) or a “RING-dead” (RΔ) Trim58
containing two missense mutations predicted to abrogate E3 ligase activity (Figure
3.11A) (Zhang et al., 2012). The cultures were treated with puromycin for 3 days to
enrich for infected cells and analyzed by Western blotting (Figure 3.11B). Although WT
Trim58 slowed cell proliferation, we were able to create viable, stably expressing lines.
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Compared to the RΔ mutant, WT Trim58 was poorly expressed, likely due its
autoubiquitylation and subsequent proteasomal degradation, which occur with other Trim
proteins (Versteeg et al., 2013). Dynein subunits DHC and DIC were nearly absent from
cells expressing WT Trim58, but not from cells expressing the RΔ version or the vector
alone (Figure 3.11B and data not shown). In order to assess the mechanism through
which Trim58 expression causes dynein loss, Trim58-expressing HeLa cells were treated
with the proteasome inhibitor MG132. As shown in the right-hand panel of Figure 3.11B,
MG132 increased the expression of dynein and WT Trim58. Thus, Trim58 promotes the
degradation of itself and of dynein via mechanisms that require E3 ubiquitin ligase
activity and proteasomes.
We then investigated whether Trim58 expression elicited cellular phenotypes
characteristic of dynein loss. Dynein transports Golgi bodies along microtubules into
perinuclear stacks at the microtubule organizing center (MTOC) (Quintyne et al., 1999).
Inhibition of dynein by overexpression of CC1, a portion of p150Glued that interferes with
the DIC-dynactin interaction, causes Golgi fragmentation and dispersal throughout the
cytoplasm (Quintyne et al., 1999). We verified this result in HeLa cells and showed that
WT Trim58, but not the RΔ mutant, produced a similar effect (Figure 3.12). Dynein also
functions in mitotic spindle checkpoint inactivation to facilitate anaphase onset (Howell
et al., 2001). Ectopic expression of WT Trim58 in HeLa cells caused mitotic defects
characteristic of dynein inhibition, including prolonged interval between cell rounding
and anaphase (Figures 3.13A and 3.13B) and cell death after rounding (Figure 3.13B
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right panel) that were significantly worse than cells expressing vector or RΔ Trim58.
Thus, ectopic expression of Trim58 in heterologous cells induces phenotypes that are
consistent with dynein deficiency.

Trim58 expression in erythroblasts coincides with loss of dynein and enucleation
We investigated whether endogenous Trim58 expression promotes dynein loss
during erythropoiesis. In murine erythroblast cultures undergoing semi-synchronous
maturation, the induction of Trim58 protein at 24 hours correlated with loss of dynein
subunits (DIC and DHC, Figure 3.14A) and the onset of enucleation (Figure 3.14C, black
bars). The absence of dynein in late stages of erythroid maturation is consistent with
proteomic studies of murine (Pasini et al., 2008) and human (Goodman et al., 2007)
erythrocytes. In contrast, Trim58-deficient cells retained dynein protein aberrantly
(Figures 3.14B and 3.15) and enucleation was delayed (Figures 3.14C gray bars). Dynein
expression still declined in Trim58 knockdown erythroblasts, but with a ~12 hr delay.
The eventual degradation of most dynein by 44 hours may be due to incomplete
suppression of Trim58 and/or alternate protein degradation mechanisms. Overall, our
findings demonstrate that expression of Trim58 destabilizes dynein and promotes
enucleation. These findings are consistent with a model in which Trim58-mediated
degradation of dynein and erythroblast enucleation are mechanistically linked.

53

We then used immunofluorescence to examine relationships between microtubule
structure and nuclear positioning during enucleation. Erythroblast nuclei are surrounded
by a network or “cage” of microtubules, similar to what occurs in most cells (Figure
3.16) (Tsai et al., 2010; Wilson and Holzbaur, 2012). During enucleation, the nucleus
moves away from the MTOC (Figure 3.20 and (Konstantinidis et al., 2012; Wang et al.,
2012)), opposite to what would occur with minus end-directed dynein transport. Later,
the microtubule cage partially collapses, becoming detached from the cell cortex and
nucleus as the latter is extruded (Figures 3.16ii-iv). Dynein stabilizes microtubules and
tethers them to the cell cortex (Hendricks et al., 2012). Thus, events observed during
enucleation, including directional nuclear movement and microtubule cage collapse
(Figure 3.17), may be facilitated by dynein loss.

Chapter commentary
In this chapter, we performed a carefully controlled characterization of the effects
of Trim58-targeting shRNA effects in a primary cell culture model of erythroid
differentiation. These data indicated that Trim58-deficiency or the shRNAs themselves
delayed erythroid enucleation, likely by disrupting the kinetics of dynein degradation. We
also performed imaging-flow cytometry studies to dissect the specific nuclear
morphology changes and movements (condensation, polarization, and extrusion) that
were inhibited by (what we now know are caused by) Trim58-directed shRNAs
54

themselves. To test the effects of complete Trim58 loss on erythropoiesis and substrate
degradation, the next step was generating and analyzing a Trim58 knockout mouse
model.
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Figures

Figure 3.1. Human Trim58 expression is restricted to late stage erythroblasts.
Human TRIM58 mRNA expression levels were measured by microarray analysis in (A) a
panel of human tissue types (Wu et al., 2009), (B) a panel of human hematopoietic tissues
(Novershtern et al., 2011), and (C) cultured primary human erythroblasts from peripheral
blood buffy coat mononucleocytes (Merryweather-Clarke et al., 2011). The results in
panel C represent mean ± SD for 3 biological replicates normalized to the average
expression level in CFU-E cells, which were assigned a value of 1. **p<0.01. CFU-E,
erythroid colony-forming units; Pro-E, proerythroblasts; Int-E, intermediate (basophilic)
erythroblasts; Late-E, late (orthochromatic) erythroblasts.
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Figure 3.2. Murine Trim58 is expressed during late stage erythropoiesis.
(A) RNA in situ hybridization for Trim58 mRNA in a day 14.5 mouse embryo showing
strong expression (red) in fetal liver, the site of definitive erythropoiesis. (B) Primary
murine fetal liver erythroblasts were FACS-purified using a previously described gating
strategy (Pop et al., 2010) and Trim58 mRNA was analyzed by semiquantitative real-time
PCR. The y-axis shows relative mRNA expression, normalized to S0 cells, which were
assigned a value of 1. The results represent mean ± SEM for 3 biological replicates.
*p<0.05. (C) Chromatin immunoprecipitation-sequencing (ChIP-Seq) analysis of
transcription factor binding to the Trim58 locus in primary murine erythroblasts (data
from Pimkin et al, in revision). The blue line depicts the Trim58 gene, with exons shown
as rectangles. Transcription factor binding sites are indicated in red.
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Figure 3.3. Trim58-directed shRNAs reduce expression in murine erythroblast cultures.
(A) Embryonic day 14.5 murine fetal liver erythroid precursors were purified, infected
with retroviruses encoding Trim58 or control shRNAs, and cultured for 24-72 hrs in
expansion medium with puromycin (Puro) to select for infected cells. The cells were then
switched to maturation medium, which facilitates development to the reticulocyte stage
over ~48 hrs. Epo, erythropoietin; SCF, stem cell factor; Dex, dexamethasone. Scale bar,
10mm. (B) Western blot for Trim58 in erythroblasts expressing Trim58-directed or
control shRNAs at 48 hrs maturation. Luc, luciferase; Scr, scrambled. The asterisk (*)
represents a nonspecific band. “Long” and “short” exposures are from the same blot. (C)
Suppression of Trim58 mRNA expression by four shRNAs. Trim58 mRNA levels were
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measured at 48 hrs maturation by semiquantitative real time PCR and normalized to the
average expression value for Gapdh, Actin, and Hprt mRNA levels. The y-axis represents
mRNA expression level compared to the average value for control-treated samples
(Vector, shLuc, shScr), which was set at 1. Results represent mean ± SD for 4 biological
replicates.
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Figure 3.4. Trim58 knockdown inhibits murine erythroblast enucleation.
FACS analysis for enucleation of control (shLuc) and Trim58-deficient (shTrim58 #4)
erythroid cultures at the indicated time points. During maturation, erythroblasts become
smaller, indicated by decreased forward scatter, and ultimately enucleate to become
Hoechst-negative reticulocytes (boxed regions). (B) Summary of percent (%) enucleation
at the indicated time points in cultures treated with control (shLuc) or Trim58-directed
(#4) shRNAs. Results represent mean ± SD for 3 biological replicates. (C) Four Trim58directed shRNAs inhibit enucleation. Following 48 hrs maturation, erythroblasts treated
with the indicated shRNAs were analyzed by FACS for enucleation. (D) Representative
histologies of control (shLuc) and Trim58-deficient (shTrim58 #4) erythroid cultures
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after 36 hrs maturation. Red arrows denote anucleate reticulocytes. Scale bar, 20 mm. R,
reticulocyte; E, erythroblast; N, extruded nucleus. (E) Summary of cell counts from panel
D showing percent (%) reticulocytes. Six hundred cells were counted on each slide.
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Figure 3.5. Trim58 knockdown results in multinucleated erythroblasts.
Murine fetal liver erythroblasts were infected with control retrovirus(es) (empty Vector;
shLuc, Luciferase; and/or shScr, Scrambled), Trim58-directed shRNA(s) (sh58 #3, #4,
#5, and/or #7) and/or mock-treated. Infected cells were expanded with puromycin for 72
hrs and then induced to mature at time 0. (A) At 48 hrs maturation, erythroblasts treated
with shTrim58 #4 were cytocentrifuged onto a glass slide, stained with May Grünwald
and Giemsa reagents, and visualized by light microscopy. Arrows denote binucleate
erythroblasts (BE). Scale bar, 10 mm. (B) The percentage of cells containing 2 or more
nuclei was quantified by visual inspection. Results represent mean ± SD for 3
independent experiments with >200 cells counted per treatment group per experiment.
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Figure 3.6. Trim58 knockdown does not affect CD44 downregulation kinetics
during erythroid maturation.
Erythroblasts expressing control (shLuc, black) or Trim58 (sh58 #4, gray) shRNAs were
analyzed serially by flow cytometry for CD44, a cell surface marker that progressively
decreases during erythroid maturation (Chen et al., 2009). Representative histogram plots
of FACS data are shown. Below the histograms are line graphs depicting CD44 mean
fluorescence intensity (mfi) over time (mean ± SD for 4 biological replicates). % max,
percent (%) of maximum cell count.
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Figure 3.7. Trim58 knockdown does not affect cell proliferation or viability.
Murine fetal liver erythroblasts were infected with control retrovirus(es) (empty Vector;
shLuc, Luciferase; and/or shScr, Scrambled), Trim58-directed shRNA(s) (sh58 #3, #4,
#5, and/or #7) and/or mock-treated. Infected cells were expanded with puromycin for 72
hrs and then induced to mature at time 0. (A) Infected erythroblast proliferation was
quantified at 0, 24, and 48 hrs maturation. Cell numbers were normalized to the cell count
at 0 hrs. Results represent mean ± SD for 4 biological replicates. (B) Cell viability was
measured by fluorescent amino-reactive (LiveDead) staining at 0, 24, and 48 hrs
maturation. Results represent mean ± SD for 4 biological replicates. A key depicting the
color of each treatment group is shown to the right.
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Figure 3.8. Trim58 knockdown does not affect Hb content or nuclear condensation.
Murine fetal liver erythroblasts were infected with control retrovirus(es) (empty Vector;
shLuc, Luciferase; and/or shScr, Scrambled), Trim58-directed shRNA(s) (sh58 #3, #4,
#5, and/or #7) and/or mock-treated. Infected cells were expanded with puromycin for 72
hrs and matured for 48 hours. (A) Hemoglobin content measured at 48 hrs maturation,
normalized to total cellular protein. Results represent mean ± SD for 3 independent
experiments. The top panel shows the red color of cell pellets. (B) Nuclear size
quantification at 48 hrs maturation. Erythroblasts treated with the indicated shRNAs were
centrifuged onto a slide and stained with May Grünwald and Giemsa reagents. The area
encompassed by each nucleus was quantified by microscopy using the Analyze Particles
feature in FIJI (Schindelin et al., 2012). Results represent mean ± SD for 3 independent
experiments with >50 cells counted per treatment group per experiment. *p<0.05,
**p<0.01.
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Figure 3.9. The Trim58 PRY-SPRY domain binds the molecular motor dynein.
(A) Domain structures of Trim58 showing the “tripartite” RING-BBox-Coiled Coil (CC)
motif and the immunoglobulin-like PRY-SPRY domain. Amino acid numbers are
indicated. In some TRIM proteins, the RING domain recruits E2 conjugases carrying
activated Ubiquitin and the PRY-SPRY domain binds substrates. (B) FLAG-tagged
Trim58 PRY-SPRY domain (PS), or vector (V), were stably expressed in G1E
proerythroblast cells. Lysates were immunoprecipitated (IP) with FLAG antibody,
fractionated by SDS-polyacrylamide gel electrophoresis, and stained with Coomassie
Blue Silver. Numbered arrows denote the regions of the gel from which bands were
excised for mass spectrometric (MS) analysis. Bands from both V and PS IPs were
analyzed. MS identified peptides from dynein heavy chain (DHC), dynein intermediate
chain (DIC), dynein light intermediate chains 1/2 (DLIC), and Trim58 PRY-SPRY (PS)
predominantly in Bands 1, 3, 4, and 5, respectively. These proteins were only identified
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in bands from the PS IP lane. See Tables 3.1 and 3.2 for a full listing of identified
proteins. Inp, input (1%). (C) Lysates of G1E cells expressing FLAG-PS or vector (V)
were immunoprecipitated with FLAG antibody and analyzed by Western blotting
(immunoblotting, IB) for DHC, DIC, FLAG and Codanin1 (Cdan1, negative control).
Inp, input (5%). (D) Embryonic day 14.5 murine fetal liver erythroblasts were lysed,
immunoprecipitated with anti-DIC antibody or IgG control and analyzed by Western
blotting for the indicated proteins. a globin was included as a negative control. Inp, input
(0.5%).
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Figure 3.10. Trim58 binds directly to the DIC amino terminus.
(A) Recombinant purified GST-Trim58 PS domain (GST-PS) or GST alone were
incubated with purified bovine holodynein complex and glutathione-Sepharose beads.
Bound proteins were analyzed by Western blotting. Equal percentages of total input
(Inp), pull down (PD) and supernatant (SN) samples were loaded. (B) 293T cells were
transfected with expression plasmids encoding hemagglutinin (HA) fused to the indicated
DIC amino acids. After 24 hrs, cells were lysed and incubated with GST-PS or GST and
glutathione-Sepharose beads. Bound proteins were analyzed by anti-HA Western
blotting. PD, pull down. SN, supernatant (1%). (C) SEC-MALLS data for PS, GST68

DIC(1-120) and a 1:1 mixture. Protein concentration was measured on an inline
refractive index detector. Light scattering data converted to molecular weight are shown
above each chromatography trace and relate to the right-hand y-axis. The observed
molecular weights are consistent with a 1:1 interaction between the two proteins
augmented by the dimerization of the GST tag appended to DIC(1-120). (D) DIC domain
structure showing the amino-terminal coiled coil (CC) motif, which binds Trim58. This
region of DIC also binds dynactin/p150Glued and NudE, which are previously
characterized regulators of dynein function (McKenney et al., 2011). The DIC carboxyterminal domain contains WD repeats that interact with DHC. Amino acid numbers are
indicated (aa#).
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Figure 3.11. Trim58 facilitates dynein degradation.
(A) Schematic diagram showing full length Trim58 constructs with amino-FLAG and
carboxyl-mCherry tags. The RD mutant contains two missense mutations in the RING
domain that abrogate ubiquitin ligase activity. (B) Western blot analysis of Trim58expressing HeLa cells. Cells were infected with retrovirus encoding FLAG-Trim58 (WT
or RD) or vector (V), selected in puromycin for 3 days, then analyzed by Western
blotting before or after treatment with the proteasome inhibitor MG132 (10 mM) for 4 hrs
at 37 ºC.
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Figure 3.12. Trim58 expression causes Golgi spreading, a marker of dynein
dysfunction.
Assessment of Golgi structure in HeLa cells expressing Trim58. HeLa cells were
transfected with expression plasmids encoding Trim58-mCherry or CC1-mCherry, a
dynein inhibitor (Quintyne et al., 1999). After 36 hrs, the cells were fixed, stained for the
Golgi matrix protein GM130 and DNA (DAPI), and visualized by confocal microscopy.
The percentage (%) of mCherry (mCh) positive cells that displayed normal punctate
perinuclear Golgi body distribution is shown at right. The results represent mean ± SD
for 3 independent experiments, with >100 cells counted per experiment. **p<0.01 vs.
Vector control.
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Figure 3.13. Trim58 expression perturbs mitotic progression.
(A) Mitotic progression in HeLa cells expressing Trim58-mCherry constructs was
analyzed by time-lapse microscopy. Representative images show mitotic progression in
outlined cells. Cells expressing WT Trim58 exhibit delayed progression from cell
rounding (~metaphase) to anaphase, compared to cells expressing vector or RD Trim58.
BF, Brightfield; mCh, mCherry. Scale bar, 16mm. (B) Quantitative analysis of mitosis in
Trim58-expressing HeLa cells. The graph on the left shows time elapsed between cell
rounding and anaphase. The results represent mean ± SD for all observed mitotic cells.
**p<0.01. The graph on the right shows the percentages of cells with delayed (>200 min)
or failed mitosis manifested as cell death between rounding and anaphase. (V, n=134
normal mitoses; WT, n=50 normal, 13 delayed, 11 failed mitoses; RD, n=100 normal, 7
delayed mitoses).
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Figure 3.14. Trim58 expression correlates with loss of dynein and enucleation
during erythroid maturation.
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Fetal liver erythroblasts were infected with retrovirus encoding shRNA against (A)
luciferase (shLuc) or (B) Trim58 (shRNA #4), cultured in expansion medium for 72 hrs,
and shifted to maturation medium at time 0. Whole cell lysates were prepared at the
indicated time points and analyzed by Western blotting. A control sample from 44 hrs
maturation was run in the lane marked “+” as a positive control for Trim58. (C) Rate of
enucleation in cells from panels A and B, determined as shown in Figure 3.4A. The
results represent mean ± SD for 4 biological replicates. *p<0.05; **p<0.01; ns, not
significant.
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Figure 3.15. Trim58 deficiency causes aberrant dynein protein retention in late
stage erythroblasts.
Erythroblast cultures expressing control constructs (Vector, shLuc) or Trim58-directed
shRNAs (sh58 #4, sh58 #7) were expanded in puromycin for 72 hrs, then induced to
mature for 48 hrs and collected for analysis. (A) Whole cell lysates were analyzed by
Western blotting for the indicated proteins. DHC, dynein heavy chain; DIC, dynein
intermediate chain. (B) Whole cell lysate cDNA was analyzed by semiquantatitive real
time PCR for dynein intermediate chain (Dync1i2), dynein heavy chain (Dync1h1) and
Trim58. The y-axis represents mRNA expression level compared to the average value for
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control-treated samples (Vector, shLuc), which was set at 1. Results represent mean ± SD
for 4 biological replicates. **p<0.01; ns, not significant.
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Figure 3.16. Directional nuclear movement during erythroblast enucleation.
Primary murine fetal liver erythroblasts were fixed, stained for microtubules (α tubulin,
green) and DNA (DAPI, blue), and imaged by deconvolution fluorescent microscopy.
Arrow indicates the microtubule organizing center (MTOC). Scale bar, 2 µm.
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Figure 3.17. Model for the actions of Trim58 during erythroblast enucleation.
In early maturation, the nucleus resides within a cage of microtubules (green) and dynein
(blue) keeps the nucleus in close proximity to the MTOC (yellow). Induction of Trim58
causes dynein degradation, which may promote nuclear polarization through multiple
mechanisms. A microtubule motor imbalance may allow unopposed kinesin molecular
motors to polarize the nucleus within a microtubule cage (top) and/or microtubule cage
collapse could free the nucleus to polarize. Following polarization and microtubule
disassembly, nuclear extrusion occurs.
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Tables
Protein Name

Accession

MW

Band

Unweighted

Unique

Percent

Spectra

Peptides

Coverage

Cytoplasmic dynein 1
Heavy chain 1

IPI00119876

532 kD

1

189

95

19

Intermediate chain 2

IPI00131086

68 kD

3

16

7

14

Light intermediate chain 1

IPI00153421

57 kD

3,4

38

12

27

Light intermediate chain 2

IPI00420806

54 kD

4

12

7

16

IPI00353647

55 kD

4,5

91

14

26

Trim58 PRY-SPRY (Bait)
Trim58

Table 3.1. Dynein subunits identified by mass spectrometric analysis of proteins that
coimmunoprecipitated with the Trim58 PRY-SPRY domain in erythroid cells.
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Chapter 4 The role of Trim58 in vivo

In this chapter, we performed experiments to follow up in vitro studies
implicating Trim58 as a necessary component of erythroblast enucleation. In the previous
chapter, we showed that Trim58 stimulated ubiquitination and proteasomal degradation
of the dynein molecular motor complex. Expression of Trim58-directed short hairpin
RNAs (shRNAs) in cultured mouse fetal liver erythroblasts caused abnormal
accumulation of dynein and delayed erythroblast enucleation. To examine the functions
of Trim58 in vivo, we disrupted the gene by removing exon 3, which encodes an essential
coiled-coil motif. Figures and Tables can be found at the end of the text.

Additional co-authors who contributed to this work:
Division of Hematology at the Children’s Hospital of Philadelphia:
Christopher Thom, Jenna M Nickas, and Olivia Y Zhou
Department of Hematology at St. Jude Children’s Research Hospital:
Yu Yao and Mitchell J. Weiss
Department of Computational Biology at St. Jude Children’s Research Hospital:
Evadnie Rampersaud, Lance Palmer
Department of Physiology and the Pennsylvania Muscle Institute at the University of
Pennsylvania Perelman School of Medicine:
Erika L Holzbaur
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Chapter Summary
Trim58 is an E3 ubiquitin ligase expressed at high levels in late stage erythroblasts.
Previous work showed that Trim58 stimulated ubiquitination and proteasomal
degradation of the dynein molecular motor complex. Expression of Trim58-directed short
hairpin RNAs (shRNAs) in cultured mouse fetal liver erythroblasts caused abnormal
accumulation of dynein and delayed terminal maturation by inhibiting extrusion of the
nucleus (enucleation). To examine the functions of Trim58 in vivo, we disrupted the gene
by removing exon 3, which encodes an essential coiled-coil motif. Erythroblasts,
reticulocytes and RBCs of homozygous targeted mice lacked Trim58 protein and
contained abnormally elevated dynein levels. The mutant mice showed mild alterations in
red blood cell size and number, consistent with genome wide association studies
(GWAS) linking the human TRIM58 gene to these traits. However, Trim58-/- mice had no
anemia at steady state and recovered normally after phenylhydrazine-induced hemolysis.
Moreover, in contrast to results obtained using RNA interference in cultured wild type
erythroblasts, Trim58-/- erythroblasts enucleated normally in the same assays. These
studies show that Trim58 eliminates dynein expression during erythroid maturation in
vivo. However, this process is largely dispensable for erythropoiesis.
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Introduction
Mature red blood cells are void of organelles and contain mainly hemoglobin,
which makes up approximately 95% of total cellular protein (Roux-Dalvai et al., 2008).
To achieve this specialized state, streamlining of the proteome occurs during erythroid
maturation via multiple mechanisms including transcriptional and post transcriptional
alterations in gene expression, and selective protein elimination, in part through
autophagy and the ubiquitin proteasome system (UPS). The UPS is a multi-enzyme
cascade that catalyzes the formation of polyubiquitin chains onto proteins at specific
lysine residues, thereby targeting them for degradation. Generalized inhibition of the UPS
by drugs or RNA interference impairs erythropoiesis (Chen et al., 2002; Egan et al.,
2015; James et al., 2007). Indeed, anemia is a recognized toxicity of bortezimib, an FDAapproved proteasome inhibitor used for treating multiple myeloma (San Miguel et al.,
2006).
The UPS facilitates selective elimination of proteins, including those that are
irreversibly damaged, cytotoxic, or unnecessary (Khandros and Weiss, 2010). This
pathway degrades target proteins through a multistep mechanism. An E1 enzyme
activates ubiquitin and transfers it to an E2 ubiquitin-conjugating enzyme. E3 ubiquitin
ligases act as scaffolds to bind the E2-ubiquitin enzyme and substrate, thereby promoting
its polyubiquitination and subsequent recognition by the proteasome, a multi-subunit
organelle that includes numerous proteases. Hundreds of different E3 ligases, each
recognizing a limited repertoire of substrates, confer specificity to the UPS.
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Transcriptome and proteomic studies showed that UPS components, including numerous
E3 ligases, are upregulated during late stages of erythroid maturation (An et al., 2014;
Egan et al., 2015; Pasini et al., 2006). However, relatively few of these E3 ligases have
been studied with respect to substrate recognition and functions during RBC formation
(Khandros and Weiss, 2010; Wefes et al., 1995).
We recently characterized Trim58, an E3 ubiquitin ligase that is strongly induced
during late stage erythropoiesis (Thom et al., 2014). In human GWAS, TRIM58-linked
nucleotide polymorphisms segregate with altered RBC size and number, implicating a
role in erythropoiesis (Ganesh et al., 2009; van der Harst et al., 2012). Trim58 is a
member of the Tripartite Motif-containing (Trim) superfamily including more than 65
proteins, many of which function as E3 ubiquitin ligases with important roles in cell
physiology (Ozato et al., 2008). The N-termini of Trim proteins contain sequential RING
(Really Interesting New Gene), B box, and coiled-coil domains, while various substrate
binding domains are present at the C-terminus (James et al., 2007). Previously, we
showed that the C-terminal PRY-SPRY domain of Trim58 binds the dynein molecular
motor complex to facilitate its ubiquitination and degradation in vitro and in cultured
cells (Thom et al., 2014). Dynein is an essential multi-subunit protein that transports
cellular cargo, including proteins, vesicles, and organelles, along microtubules toward the
minus-end. Expression of Trim58-targeting short hairpin (sh) RNAs in cultured fetal liver
erythroblasts prevented dynein elimination during terminal maturation and delayed
enucleation that occurs during normal RBC formation. Thus, we proposed that Trim5883

mediated degradation of dynein facilitates erythroid maturation by promoting
enucleation.
To examine further the role of Trim58 in erythropoiesis, we disrupted the
corresponding gene in mice. Removal of exon 3, which encodes an essential coiled-coil
domain, largely eliminated both ubiquitin ligase activity towards dynein and Trim58
expression in erythroblasts. Nucleated erythroblasts, reticulocytes and mature red blood
cells from Trim58-/- mice contained abnormally elevated levels of dynein. The mutant
mice also exhibited altered RBC number and size (mean corpuscular volume, MCV),
consistent with GWAS, which linked the human TRIM58 gene to these traits. However,
Trim58-/- mice had no anemia at baseline and recovered normally after phenylhydrazineinduced hemolysis. Moreover, terminal maturation of cultured Trim58-/- fetal liver and
adult erythroblasts, including enucleation, was normal. Furthermore, we showed that
Trim58 shRNAs inhibit enucleation of cultured mouse erythroblasts through sequenceindependent off-target effects that vary according to genetic strain. Collectively, our
studies demonstrate that Trim58 promotes degradation of dynein in vivo, but is largely
dispensable for erythropoiesis and thrombopoiesis.
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Results
Disruption of the Trim58 gene.
The first intron of Trim58 contains a predicted erythroid enhancer identified by a
DNase I hypersensitive site and binding of the transcription factors Gata1 and Tal1
(Thom et al., 2014). Our targeting strategy preserved this region, as intergenic enhancers
can potentially regulate distant genes (Harmston and Lenhard, 2013). We removed
Trim58 exon 3 (Figures 4.1A and 4.2A), which encodes a coiled-coil domain required for
ubiquitin ligase activity of other Trim family members (Sanchez et al., 2014). Mutant
mice, referred to as Trim58-/- for reasons discussed below, were born at normal
Mendelian ratio, exhibited no obvious morphological abnormalities and survived to
adulthood. We verified correct targeting of the Trim58 locus by Southern blotting (Figure
4.11B), PCR of genomic DNA (Figure 4.1C) and quantitative reverse transcription PCR
(RT-PCR) of E14.5 fetal liver cells (Figure 4.2A-B). Homozygous and heterozygous
mutant erythroblasts expressed an aberrant Trim58 mRNA that included exons 1 and 2,
but lacked distal sequences (Figures 2A-B and 4.3A). Thus, the mutant gene is probably
transcribed at normal rate, but largely processed abnormally with loss of sequences that
are distal to deleted exon 3 (Figure 4.2B, right).
Excision of Trim58 exon 3 creates an in-frame deletion of 77 amino acids. In
principle, this could generate a mature RNA encoding an internally deleted form of
Trim58 protein that lacks only the coiled-coil region, but contains the RING, B-box and
PRY-SPRY domains (Figure 4.3B). This Trim58 transcript, termed ΔCC, was expressed
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in homozygous mutant erythroblasts (Figure 4.3A), albeit at very low levels (Figure 4.2B,
right panel). ΔCC or wild type (WT) Trim58 proteins were not visualized in Western blot
studies of Trim58-/- fetal livers (Figure 4.2C) or circulating reticulocytes from adult
mutant animals (Figure 4.10C, below). Nonetheless, we assessed potential functions of
the Trim58 ΔCC protein by transducing NIH3T3 cells with retroviruses encoding
FLAG/mCherry-tagged versions of either WT Trim58, Trim58 ΔCC, or a “RING-dead”
(RΔ) Trim58 containing two missense mutations that eliminate E3 ubiquitin ligase
activity (Figure 4.3B-C). In contrast to Trim58-/- erythroblasts, Trim58 ΔCC was stably
expressed in NIH3T3 cells. However, unlike WT Trim58, ectopically expressed ΔCC
Trim58 failed to eliminate dynein (Figure 4.3C). Overall the mutant protein is expressed
in heterologous cells, although it does not degrade dynein, in agreement with studies
demonstrating that the CC domain is necessary for ubiquitin ligase activity (Sanchez et
al., 2014). However, Trim58 ΔCC mRNA and protein are expressed minimally in
Trim58-/- erythroblasts. Thus, we conclude that ablation of exon 3 eliminated endogenous
erythroid Trim58 activity.

Normal hematopoiesis in Trim58-/- mice with a mixed genetic background.
Initially, we analyzed Trim58-/- mice with a mixed genetic background (Sv129,
FVB, and C57Bl/6). No major differences in erythroid parameters occurred in mutant
mice compared to WT littermates, although we observed trends toward decreased RBC
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number and increased mean corpuscular volume (MCV) (Table). Fetal liver, bone
marrow and splenic erythroid precursors were normal in number and no maturation
defects were evident by flow cytometry analysis of cell surface markers Ter119 and
CD71 (Figures 4.4 and 4.5). Adult Trim58-/- mice exhibited normal recovery after anemia
induced by phenylhydrazine (Figure 4.5C).

Trim58-/- erythroblasts undergo normal enucleation in vitro.
Previously, we showed that multiple shRNAs targeting different regions of
Trim58 mRNA inhibited enucleation of cultured WT fetal liver erythroblasts (Thom et
al., 2014). We performed similar studies on E14.5 fetal liver erythroblasts from the
progeny of intercrossed Trim58+/- mice. Erythroblasts were expanded for 1-3 days by
culturing in dexamethasone, stem cell factor, and erythropoietin (Epo), followed by
removal of the first two components to induce terminal maturation. We monitored
erythroblast enucleation by flow cytometry of cells stained with the erythroid antigen
Ter119 and Hoechst 33342, a cell permeable nuclear dye (Figure 4.6A). Surprisingly,
Trim58-/- fetal liver erythroblasts enucleated normally after 24 and 48 hours of maturation
(Figure 4.6B), contrasting with our previous results obtained after expression of Trim58
shRNAs in E14.5 erythroblasts (strain CD1) (reference (Thom et al., 2014) and Figure
4.6C). This apparent discrepancy could be due to strain-specific effects of either Trim58
deficiency or Trim58 shRNAs. Two independent Trim58 shRNAs had no effect on the
enucleation of mixed strain (Sv129, FVB, and C57Bl/6) Trim58-/- or Trim58+/+
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erythroblasts (Figure 4.7A), despite effective reduction of Trim58 mRNA in mixed strain
WT cells (Figure 4.7B).

Trim58-/- mice with C57Bl/6 background have mild hematological abnormalities.
To investigate further potential strain effects of Trim58 deficiency, we bred
Trim58-/- alleles onto a pure C57Bl/6 background. Similar to what we observed on the
mixed genetic background, C57Bl/6 Trim58-/- mice were not anemic (Table 4.1) and
RBC morphologies on blood smears were normal (not shown). Trim58-/- C57Bl/6 mice
exhibited mild but significantly decreased RBC number and increased MCV (Table 4.1),
similar to the trends observed in Trim58-/- mixed background mice. Of note, GWAS
studies link the human TRIM58 gene to variations in RBC number, MCV (Gieger et al.,
2011; Kamatani et al., 2010; van der Harst et al., 2012). Human GWAS studies also link
TRIM58 allelic variation to altered platelet count; this parameter trended downward in
Trim58-/- mice, but was not significant (p=0.09 and p=0.2 for mixed genetic background
and C57/Bl6 strains, respectively).

Trim58-/- mice with C57Bl/6 background reveal strain-specific shRNA off-targeting.
Remarkably, two different Trim58 shRNAs reduced enucleation of C57Bl/6
erythroblasts by 25-35%, regardless of Trim58 genotype (+/+ or

-/-

) (Figure 4.8A). As

expected, the shRNAs effectively reduced full-length Trim58 mRNA in C57Bl/6
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erythroblasts (Figure 4.8B). To summarize, Trim58 gene disruption in mixed or C57Bl/6
backgrounds produced mild alterations in RBC number and MCV, with no effects on in
vitro enucleation of cultured erythroblasts. In contrast, two shRNAs targeting nonoverlapping segments of Trim58 mRNA inhibited enucleation of cultured CD1 and
C57Bl/6 erythroblasts, but had no effects on erythroblasts with mixed genetic
background. Thus, the effects of Trim58 shRNAs on erythroblast enucleation are genetic
strain-specific and occur through mechanisms that are independent of Trim58
suppression.

Increased dynein in Trim58-/- erythroblasts.
To investigate whether Trim58 promotes dynein degradation in vivo, we
compared its expression in erythroid cells of WT and Trim58-/- mice (mixed strain,
Sv129/FVB/C57Bl/6). We phlebotomized animals to induce semi-synchronous
erythropoiesis (Figure 4.9A) and collected bone marrow and circulating RBCs at various
stages of maturation. Trim58+/+ and Trim58-/- erythroblasts were purified from the bone
marrow by Ter119 immunomagnetic bead selection; cells of both genotypes were of
similar maturation stage, based on Ter119 and CD71 expression (Figure 4.9B). Although
dynein is expressed in most cells, levels decrease during erythroid maturation (Thom et
al., 2014), as evidenced in the current study by Western blotting for dynein intermediate
chain (IC) in WT Ter119+ bone marrow erythroblasts (Figure 4.9C). In contrast, Trim58-/-
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erythroblasts expressed dynein IC at a level similar to that of unfractionated bone
marrow.
Next, we used a Percoll gradient to purify circulating reticulocytes and mature
RBCs (Blanc et al., 2009) (Figure 4.10A). Coomassie blue silver stain showed no
obvious differences in the protein content of WT vs. Trim58-/- reticulocytes (Figure
4.10B). Trim58 protein was not detected by Western blotting in homozygous mutant
reticulocytes (Figure 4.10C). However, Trim58-/- reticulocytes (Figure 4.10C) and RBCs
(Figure 4.10D) expressed abnormally elevated levels of dynein IC. Together, these data
are consistent with previous findings that Trim58 ubiquitinates dynein IC to facilitate
degradation of the dynein complex (Thom et al., 2014). The current data demonstrate that
Trim58 promotes dynein degradation during erythropoiesis in vivo, although
accumulation of dynein upon loss of Trim58 has minimal consequences on RBC
formation at baseline or during recovery of induced hemolytic anemia, and no effect on
enucleation of cultured erythroblasts.

Chapter commentary
Here, we discovered an unusual phenotype caused by shRNAs, found to be
independent of Trim58 mRNA suppression. This is discussed further in Chapter 6. These
studies emphasize the importance of follow-up studies and the caution necessary in
interpreting results using a single experimental approach (i.e. shRNA-induced
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knockdown in fetal liver erythroblasts). Overall, we felt it was important to gain a deeper
understanding of these effects in such a commonly used model system of erythroid
differentiation and maturation. This commitment drove us to test the effects of shRNAs
on different strains of mice and subsequently backcross the Trim58-/- allele onto a
penetrant background.
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Figures

Figure 4.1. Generation of Trim58-/- mice.
(A) Design of Trim58-/- mice. LoxP sites were inserted around exon 3, and Cre
recombinase expression mediated excision in the ES cells. (B) Southern blot of targeted
ES cell clones with predicted StuI pattern. (C) Validation of PCR amplification used for
genotyping genomic DNA.
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Figure 4.2. Disrupted Trim58 expression in Trim58-/- mice.
(A) Trim58 gene structure (not drawn to scale). The asterisk denotes the epitope for an
anti-peptide antibody (amino acids 7-29). Half arrows indicate primer pairs used for qRTPCR analysis of mRNA expression (see panel B). Exon 3, which was deleted in the gene
targeted mice, and the corresponding PCR primers are shown in grey. (B) Quantitative
RT-PCR analysis of E14.5 fetal liver mRNA from wild type (+/+), heterozygous (+/-), and
Trim58-null (-/-) embryos using the primer pairs shown in panel A. The results represent
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mean ± standard deviation for 3 biological replicates. (C) Western blot of E14.5 fetal
liver using the anti-peptide antibody described in panel A. β-actin was used as a loading
control. Arrow denotes the predicted molecular weight (50 kD) of protein with deleted
exon 3.
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Figure 4.3. Trim58-/- mice express an inactive Trim58 allele, ΔCC.
(A) Non-quantitative reverse transcription-PCR of E14.5 fetal liver cells to detect variant
Trim58 mRNA. Higher band represents full-length Trim58 expression in WT, and the
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lower band detected in heterozygotes and ΔCC represents truncated mRNA excluding
exon 3. (B) Schematic of Trim58 expression constructs with N-terminal FLAG and Cterminal mCherry tags. The RΔ mutant contains two missense mutations in the RING
domain that abolish E3 ubiquitin ligase activity. The ΔCC cDNA was cloned from
Trim58-/- fetal liver tissue. (C) Western blot analysis of Trim58-expressing NIH3T3 cells.
Cells were infected with retrovirus expressing FLAG-Trim58 (WT, RΔ, or ΔCC) or
empty vector (V), selected in puromycin for 3 days, then analyzed by Western blot for
dynein IC, FLAG, and actin for loading control.
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Figure 4.4. Normal erythropoiesis in Trim58-/- embryos with mixed genetic
background (Sv129, FVB, and C57Bl/6).
(A) Flow cytometry analysis of E14.5 fetal liver cells for CD71 and Ter119 expression.
The data shown are representative from two experiments examining two different litters.
(B) Quantitation of plots for each population shown in panel C, represented as mean ±
SD. n = 7 for each group, from three E14.5 pregnancies. Means were ns by student’s ttest.
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Figure 4.5. Normal adult erythropoiesis in E14.5 Trim58-/- mice.
(A) Quantitation of Ter119+, CD71high and Ter119+, CD71low erythroid cells in bone
marrow isolated from mice (age 8-12 weeks), evaluated by flow cytometry. Results are
shown as mean ± SD (n = 3). Means were ns by student’s t-test. (B) Quantitation of
Ter119+ erythroid cells in spleens isolated from mice (age 8-12 weeks). Results are
shown as mean ± SD (n = 3). Means were ns by student’s t-test. (C) Recovery of
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Trim58+/+, Trim58+/- and Trim58-/- mice after phenylhydrazine (PHZ)-induced hemolysis.
Arrows indicate treatments with PHZ (60 mg/kg). Serial hematocrit measurements were
performed on peripheral blood. n = 4 for each group; each time point was ns by student’s
t-test.
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Figure 4.6. Trim58-/- and Trim58-deficient erythroblasts from mixed strain mice
mature normally in vitro.
(A) Fetal liver erythroblasts isolated from E14.5 embryos (from heterozygous crosses)
were cultured in erythroid expansion medium containing for 72 hours, then switched to
maturation medium. Flow cytometry analysis is shown after 24 hours in maturation
medium. Cells were stained with the erythroid maturation marker Ter119 and the cell
permeable DNA dye Hoechst 33342 to assess percent (%) enucleated reticulocytes,
indicated by the boxes. (B) Percent enucleated erythroblasts in fetal liver cultures at 24
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and 48 hours of maturation. Data are expressed as mean ± SD for Trim58+/+ (n=6),
Trim58+/- (n=6), and Trim58-/- (n=10) embryos. (C) Enucleation of CD1 outbred strain
erythroblasts. Data are presented as mean ± SD. Data are presented as mean ± SD.
*p<0.05.
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Figure 4.7. Trim58-directed shRNAs do not inhibit enucleation in fetal liver
erythroblasts with mixed genetic background.
(A) Enucleation of mixed genetic background (Sv129, FVB, and C57Bl/6) Trim58+/+ and
Trim58-/- erythroblasts, with and without Trim58-directed shRNAs. Cells were analyzed
after 36 hours of maturation. (B) Trim58 mRNA levels determined by quantitative RTPCR is shown in the left panel. Data are presented as mean ± SD. *p<0.05.
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Figure 4.8. Trim58 knockdown in wild type and Trim58-/- C57Bl/6 fetal liver
erythroblasts reveals strain-specific off-target effect of shRNAs.
(A) Enucleation of C57Bl/6 Trim58+/+ and Trim58-/- erythroblasts, with and without
Trim58-directed shRNAs. (B) Trim58 mRNA levels determined by quantitative RT-PCR
is shown in the left panel. Data are presented as mean ± SD. *p<0.05. Cells were
analyzed after 36 hours of maturation.
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Figure 4.9. Trim58-/- erythroid cells in adult bone marrow accumulate dynein in vivo.
(A) Experimental scheme. Adult mice were subjected to phlebotomy (phleb), with 200µL
blood removed on days 0 and 2. Peripheral blood and bone marrow were collected on day
4. (B) Ter119+ erythroblasts were isolated from bone marrow by immunomagnetic
selection and analyzed by flow cytometry. (C) Western blot analysis for dynein
intermediate chain (IC) in Ter119+ erythroblasts and whole bone marrow (BM) from
Trim58+/+ and Trim58-/- mice.
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Figure 4.10. Trim58-/- erythroid cells in adult peripheral blood accumulate dynein in
vivo.
(A) Whole blood fractionated by a Percoll gradient to isolate reticulocytes and red blood
cells (RBCs). (B) Reticulocyte lysates analyzed by SDS-polyacrylamide gel
electrophoresis and Coomassie blue silver stain. (C) Western blot analysis for dynein IC,
Trim58 and β-actin in Trim58+/+ and Trim58-/- reticulocytes. (D) Western blot analysis
for dynein IC, Trim58 and β-actin in Trim58+/+ and Trim58-/- RBCs.
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Tables
Sv129/FVB/Bl6

C57Bl/6

Trim58+/+
(n = 3)

Trim58-/(n = 3)

Trim58+/+
(n = 12)

Trim58-/(n = 6)

Hemoglobin

13.5±0.8

14.0±0.5

15.0±0.4

14.8±0.4

Hematocrit (%)

40.3±4.2

39.7±5.9

47.5±2.9

48.4±2.2

MCV

44.8±0.9

48.8±3.1

51.2±3.1

55.4±3.2 *

MCH

16.4±0.6

16.8±0.9

16.1±0.4

16.9±0.8

MCHC

33.9±5.5

35.7±6.1

31.2±1.7

30.5±1.3

RDW

16.9±0.7

17.3±0.5

17.6±1.0

18.3±0.7

RBC

10.0±0.2

9.7±0.3

9.3±0.4

8.7±0.4 *

Reticulocytes (%)

4.2±1.2

3.0±0.3

3.2±0.2

3.5±0.3

Platelets

771±167

549±94

830±103

794±56

WBC

1.9±1.0

2.6±1.2

7.0±2.0

5.2±2.5

Neutrophil (%)

16.4±4.5

17.2±1.6

13.7±3.6

12.2±3.4

Lymphocyte (%)

77.4±4.1

78.1±2.4

83.8±3.2

85.6±4.3

Monocyte (%)

4.9±2.4

4.2±1.2

2.4±1.2

2.1±0.6

Eosinophil (%)

1.0±1.3

0.4±0.4

0.1±0.1

0.1±0.1

Table 4.1. Complete blood counts of mixed background (Sv129/FVB/Bl6) and
C57Bl/6 Trim58+/+ and Trim58-/- mice (age 8 to 12 weeks).
The numbers of mice analyzed from each group are shown in parentheses. MCV, mean
corpuscular volume (fL); MCH, mean corpuscular hemoglobin (pg); MCHC, mean
corpuscular hemoglobin concentration (g/dL); RDW, red blood cell distribution width
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(%); RBC, red blood cell number (x 106/µl); platelets (x 103/µL); WBC, white blood cells
(x 103/µL). * p < 0.05, student’s t-test.
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Chapter 5 Genome editing recreates hereditary persistence of fetal hemoglobin
(HPFH)

The first two chapters were inspired by studies of common human genetic
variants associated with mild effects on RBC parameters. I became interested in studying
rare mutations that caused more extreme phenotypes. Three additional factors influenced
my investigation of fetal hemoglobin regulation, including 1) its clear relevance to human
health; 2) the Weiss lab moved from Penn to St. Jude Children’s Research Hospital, an
institute with a long-standing priority of serving a large cohort of patients with sickle cell
disease; and 3) the Trim58-/- mice were rederived at St. Jude and had reproducibly intact
erythropoiesis. These studies were published in Nature Medicine (2016). Figures and
Tables can be found at the end of the text.

Additional co-authors who contributed to this work:
Department of Hematology at St. Jude Children’s Research Hospital: Yu Yao, YongDong Wang, Kaitly J. Woodard, Chunliang Li, and Mitchell J. Weiss
RIKEN BioResource Center: Ryo Kurita and Yukio Nakamura
Weatherall Institute of Molecular Medicine, Oxford University: Jim R. Hughes
Pennsylvania State University: Ross C. Hardison
Division of Hematology at the Children’s Hospital of Philadelphia: Gerd A. Blobel
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Chapter summary
Disorders resulting from HBB (β-globin) gene mutations, mainly sickle cell
disease (SCD) and β-thalassemia, become symptomatic postnatally as fetal γ-globin
expression from two parologous genes HBG1 and HBG2 falls and adult β-globin
increases, thereby shifting red blood cell (RBC) hemoglobin from the fetal (HbF, α2γ2)
to adult form (HbA, α2β2). These disorders are alleviated when postnatal expression of
fetal γ-globin is maintained. For example, in hereditary persistence of fetal hemoglobin
(HPFH), a benign genetic condition, mutations attenuate γ-to-β switching, causing highlevel HbF expression throughout life. Co-inheritance of HPFH with β-thalassemia or
SCD mutations alleviates their clinical manifestations. Here we performed CRISPRCas9-mediated genome editing of human blood progenitors to mutate a 13-nucleotide
HBG1 and HBG2 promoter sequence, thereby recapitulating a naturally occurring HPFHassociated mutation. Edited progenitors produced RBCs with increased HbF levels that
were sufficient to inhibit pathological hypoxia-induced RBC morphologies of SCD. Our
findings identify a potential DNA target for genome editing-mediated therapy of
β-hemoglobinopathies.

Results
Typical HPFH mutations include heterozygous deletions or nucleotide (nt)
substitutions within the extended β-globin locus (Forget, 1998). For example, the -175
T>C HBG1 substitution de-represses γ-globin by creating a binding site for the
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transcriptional activator TAL1 (Wienert et al., 2015). Other forms of HPFH may be
associated with loss of cis elements that recruit γ-globin repressor proteins. We focused
on a 13-nt deletion within the HBG1 (Ag) promoter (-102 to -114, Figure 5.1) (Gilman et
al., 1988). The deleted region contains a CCAAT box and direct repeat (DR), both of
which recruit transcriptional repressor proteins (Liberati et al., 2001; Mantovani et al.,
1989; Ronchi et al., 1995; Superti-Furga et al., 1988; Zhu et al., 2012). In heterozygous
individuals approximately 30% of all RBCs express HbF protein (in individuals lacking
the mutation <1% RBCs express HbF), which is potentially therapeutic for
hemoglobinopathies, as SCD patients with this level of HbF are asymptomatic (Hoban et
al., 2016). We reasoned that a DNA break induced by site-directed CRISPR/Cas9
mutagenesis, followed by error-prone non-homologous end joining (NHEJ) might
recapitulate effects of the 13-nt-deleted HPFH mutation (Doudna and Charpentier, 2014).
We used lentivirus to express mCherry, Cas9 and 2 different guide RNAs (gRNAs)
targeting this region in the erythroblast cell line HUDEP-2, which expresses mainly HbA
(Kurita et al., 2013) (Figure 5.1). HbF protein levels were undetectable in mock infected
and Cas9 only expressing control cultures and rose to approximately 17% and 3% in cells
expressing mCherry, Cas9 and gRNA-1 or gRNA-2, respectively (Figure 5.3A). Cells
staining positive for HbF (“F-cells”) increased from 2% to 46% with gRNA-1, and to
26% with gRNA-2 (Figure 5.2A). The %HBG1/2 mRNA [γ/(γ + β)] was increased by
both gRNAs; HBB mRNA expression was decreased by gRNA-1 (Figure 5.3B-C).
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Induction of HbF by two adjacent non-overlapping gRNAs suggests that the effect is due
to on-target mutations rather than to off-target mutations.
Next, we used the same mCherry/Cas9/ gRNA-encoding lentiviral vectors to edit
peripheral blood CD34+ hematopoietic stem/progenitor cells (HPSCs) from two healthy
adults. Transduced HPSCs expressing mCherry were enriched by cell sorting and then
induced to undergo erythroid differentiation. HbF protein rose from approximately 5% to
20% (Figure 5.2B), and F-cells increased from 18% to 54% in erythroid progeny of
Cas9/gRNA-1-expressing CD34+ cells (Figure 5.2C); gRNA-2 produced similar effects
of lesser magnitude. Gene editing did not alter the expression of erythroid stage-specific
maturation markers (Figure 5.4A-D). In FACS-purified a4-integrin+/Band3+ late
basophilic erythroblasts, gRNA-1 increased %HBG1/2 mRNA from 4% to 35% and
decreased absolute HBB mRNA by about 50% (Figure 5.4E-F). Increased γ-globin with
decreased β-globin expression indicates reversal of the γ-to-β switch, which is controlled
by competition of the corresponding genes for an upstream enhancer, termed locus
control region (LCR) (Palstra et al., 2008).
To test potential therapeutic effects of this genome-editing approach, we edited
patient-derived

CD34+

HSPCs

from

three

SCD

patients,

induced

erythroid

differentiation, and examined the RBC progeny. Deoxygenated HbS forms rigid
polymers that underlie the characteristic RBC morphology and pathophysiology of SCD,
while increased levels of HbF inhibit this process. To test the effects of genome editing
on HbS polymerization, we cultured SCD CD34+ cell-derived RBCs under hypoxia (2%
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O2). Approximately 30-40% of control and gene-edited cells matured to reticulocytes,
late stage anucleate RBC precursors (Figure 5.5A). Consistent with previous reports,
control (mock transduced or Cas9 alone) cultures contained relatively high percentages of
F-cells (approximately 65%) (Akinsheye et al., 2011; Kidoguchi et al., 1978), although
25% of the cells within the entire population exhibited sickle morphology, presumably
because HbF was absent in those cells or expressed at insufficient levels to prevent HbS
polymerization (Figure 5.5B). In contrast, Cas9 + gRNA-1 expression increased F-cells
to 90% and reduced sickle morphology to 4% (Figure 5.6A-B). Thus, targeting the -102
to -114 HPFH region inhibited HbS polymerization in cultured reticulocytes. Residual
sickling in Cas9/gRNA-1-expressing RBCs could occur from lack of editing or mutations
that do not induce HbF.
CRISPR/Cas9 creates targeted double-strand DNA breaks that are repaired via
error-prone NHEJ, causing nt insertions and deletions (indels). g-globin is expressed
from tandem homologous genes, HBG2 and HBG1 (Figure 5.7A). While the naturally
occurring 13-nt HPFH deletion alters HBG1, HBG2 contains an identical region that is
mutated in different HPFH individuals (Forget, 1998; Stamatoyannopoulos, 2005). To
characterize the mutations induced by Cas9/gRNA-1-expressing lentivirus in CD34+
cells, we PCR-amplified a 431-nt region surrounding the predicted cleavage sites in
HBG2 or HBG1 and deep-sequenced the products. In 3 biological replicate experiments,
the indel incidence in all transduced cells was 56, 65 and 77%, with equal mutation rates
in HBG1 and HBG2 (not shown). Approximately half of the mutations were identical to
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the -102 to -114 HPFH deletion (not shown). Most likely, the 13-nt deletion
predominates because the Cas9 cleavage site is flanked by 8-nt tandem repeats that
facilitate microhomology-mediated end-joining (Truong et al., 2013). To identify
mutations associated with g-globin induction, we purified low-, intermediate-, and highHbF erythroblasts and analyzed the promoter regions by deep sequencing (Figure 5.7B).
In 4 independent experiments, the 13-nt HPFH deletion was enriched in HbF-high cells
(p<0.05) (Figure 5.8a and Figure 5.7C).
Transduction of CD34+ cells with Cas9/gRNA-1 lentivirus produced numerous
indels smaller than 13 nt (Figure 5.8a and Figure 5.7C), although their low frequencies
impeded efforts to determine the effects on HbF expression. Thus, we performed clonal
studies by expressing gRNA-1/Cas9 in CD34+ cells transiently via DNA electroporation
followed by methylcellulose culture to analyze single cell-derived burst-forming uniterythroid (BFU-E) colonies (Figure 5.9 and Figure 5.10). Of 344 colonies screened from
3 experiments, 30 had on-target mutations, with 16 containing at least one 13-nt HPFH
deletion (Figure 5.10). All BFU-E colonies analyzed were mosaic for HBG1/2 mutations,
reflecting editing over several progenitor divisions. HBG1 and HBG2 were mutated
equally. The mutation frequencies correlated moderately with %HBG1/2 mRNA levels in
each colony (Figure 5.9) (r2=0.41, P < 0.0001). Several small indels within the CCAAT
box and/or DR were associated with elevated γ-globin expression in one or more colonies
(Figure 5.10). We also derived HUDEP-2 cell clones after transient Cas9/gRNA-1
expression, including three lines with small (1-4 nt) bi-allelic HBG1/HBG2 CCAAT box
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mutations and strong γ-globin induction (Figure 5.11A-C and Figure 5.12). HUDEP
clone 6 (Figure 5.11C) and BFU-E colony 4 (Figure 5.10) contained single-nt HBG1 and
HBG2 insertions that preserved the core CCAAT box element and altered the DR, but
was not associated with elevated γ-globin expression.
Simultaneous double-stranded DNA cleavage at gRNA-1 recognition sites in the
HBG2 and HBG1 promoters could result in NHEJ-mediated joining of the two ends with
loss of the intervening 5.2 kb. Indeed, we identified this deletion in several genome
edited HUDEP-2 clones (Figures 5.13 and 5.14). We determined the frequency of this
event in transiently edited cells using quantitative PCR (qPCR) and fluorescence in situ
hybridization (FISH) (Figure 5.13A). The 5.2-kb deletion was not detected in HUDEP-2
cells after electroporation of 2 mg Cas9/gRNA-1 DNA plasmid, but occurred in about
20% of HBG1/2 alleles after 10 mg DNA transfection (Figure 5.13B-C). The deletion
was not detected by qPCR in human CD34+ HSPCs electroporated with 10 mg
Cas9/gRNA-1 plasmid (Figure 5.14). Lastly, deep sequencing of CD34+ cells after
lentiviral delivery of Cas9/gRNA-1 showed no indels at the top 15 bioinformatically
predicted off-target sites (Table 5.1).
The -114 γ-globin promoter CCAAT box and overlapping DR element likely
mediate postnatal γ-to-β globin switching by recruiting transcriptional repressors in a
developmentally regulated fashion (Forget, 1998; Stamatoyannopoulos, 2005). Candidate
CCAAT box binding proteins include COUP-TFII (NR2F2) (Liberati et al., 2001), NF-Y
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(CP-1, CBF) (Liberati et al., 2001; Zhu et al., 2012), NF-E3 (Mantovani et al., 1989;
Ronchi et al., 1995), CDP (Mantovani et al., 1989; Superti-Furga et al., 1988), and
C/EBP (Superti-Furga et al., 1988); the DR element, binds nuclear hormone receptors
TR2 and TR4 (Tanabe et al., 2002). Although the molecular triggers of γ-to-β
globin switching are not fully defined, the current study shows that disruption of the -114
HBG1/HBG2 CCAAT box/DR region via gene editing partially reverses the switch in
adult-type erythroid cells and delineates further the cis elements involved. Importantly, γglobin induction can occur via small (< 13 nt) NHEJ-associated mutations caused by
transient editing and independent of microhomology-mediated end-joining, which is
preferentially utilized during S-phase and may not occur efficiently in hematopoietic
stem cells (Truong et al., 2013).

Chapter commentary
Genome editing technologies to manipulate hematopoietic stem cells have fueled
innovative strategies for treating β thalassemia and SCD, including correction of the SCD
mutation by homology-directed DNA repair (Hoban et al., 2015), reactivation of γ-globin
via forced promoter-LCR looping (Deng et al., 2014) or disruption of the repressor gene
BCL11A via NHEJ (Canver et al., 2015). These approaches are untested in patients. Here
we present an additional approach; CRISPR-Cas9-mediated disruption of an HBG1/2
region associated with a benign human condition (HPFH) induces HbF expression to
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potentially therapeutic levels, similar to those achieved via forced DNA looping or
Cas9/gRNA-mediated disruption of a BCL11A erythroid enhancer. Future studies are
now required to optimize editing of the γ-globin CCAAT box/DR site in human
hematopoietic stem cells and minimize potentially harmful off-target mutations. Overall,
our study provides proof-of-principle for a potential approach to treat common
hemoglobinopathies by genome editing.
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Figures

Figure 5.1. Extended β-globin locus.
Extended β-globin locus showing β-like genes as boxes. Small arrows mark DNase I
hypersensitive sites within the locus control region, an upstream enhancer. A region of
the HBG1 promoter is shown numbered according to position upstream of the
transcription start with the 13-nt HPFH deletion boxed. Guide RNA spacer sequences are
blue and PAM motifs (NGG) are orange; gRNA-1 and gRNA-2 are complementary to the
sense and antisense strands, respectively. Large arrows show predicted Cas9 cleavage
sites.
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Figure 5.2. Genome editing of the HBG1 and HBG2 promoters increases erythroid
fetal hemoglobin (HbF) levels.

(a) Representative flow cytometry plots showing HbF+ immunostaining HUDEP-2 cells
5d after transduction with Cas9 ± gRNA-1 or gRNA-2 lentivirus. Numbers indicate mean
± standard error (SE) from four independent experiments.

(b) Normal human CD34+ cells transduced with lentivirus encoding Cas9 ± gRNA-1 or
gRNA-2 were cultured for 21d in erythroid cytokines, then analyzed for hemoglobin (Hb)
protein by HPLC. %HbF = [HbF/(HbA + HbF) × 100]. Each dot represents a separate
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experiment performed with CD34+ cells from the same donor. On-target editing rates of
HBG1/HBG2 in three experiments were 56%, 65% and 77%.
(c) HbF+ erythroblasts, derived as described for panel (b). Numbers indicate mean ± SE
from three experiments.
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Figure 5.3. Genome editing of the HBG1 and HBG2 promoters reverses the γ-to-β
globin switch in HUDEP-2 cells.
HUDEP-2 cells were transduced with lentivirus expressing mCherry and Cas9 ± gRNAs.
mCherry+ cells were purified by FACS, cultured for 3 days, then analyzed. (a)
Quantification of HbA (α2β2) and HbF (α2γ2) proteins in undifferentiated HUDEP-2
cell cultures expressing Cas9 ± gRNA-1 or -2 by high performance liquid
chromatography (HPLC). Shown below are indel allele frequencies, expressed as
percentages of all alleles, as determined by PCR amplification and next generation
sequencing using primers depicted in Supplementary Fig. 4a. Coverage for each nt
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position sequenced was over 97,000x. (b) Quantitative real-time PCR analysis showing
%HBG1/2 (γ-globin) mRNA [γ/(γ + β)] in gene-edited and control cells. n = 3, shown as
mean value ± standard error (SE). (c) HBB (β-globin) mRNA levels in genome-edited
and control cells, expressed as fold change vs. mock-transduced cells. n = 3, mean value
± SE. ** P < 0.01, *** P <0.001, **** P < 0.0001 by unpaired t-test.
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Figure 5.4. Genome editing of the HBG1 and HBG2 promoters in CD34+ cells
reverses the γ-to-β globin switch in erythroid progeny without altering
differentiation or maturation.
CD34+ hematopoietic stem and progenitor cells (HSPC) from a healthy donor were
transduced with lentivirus expressing Cas9 or Cas9/gRNA-1, mCherry+ cells were FACS
122

enriched, cultured under conditions favoring erythroid differentiation and analyzed by
flow cytometry for developmental stage specific markers. The plots shown are
representative of three experiments. (a) Erythroid maturation markers CD71 and CD235
on culture day 21. (b) CD45 expression on culture day 21. (c-d) α4-integrin
downregulation and Band3 upregulation between d14 and d21 of erythroid maturation.
Cells in gates outlined in black were isolated by FACS and analyzed by qRT-PCR for
%HBG1/2 (γ-globin) mRNA in panel (e) and (f) HBB (β-globin) mRNA levels, relative
to mock-transduced cells. Overall indel frequencies for three independent experiments in
CD34+ cells were 56, 65, and 77%. * P <0.05, ** P < 0.01, *** P < 0.001, **** P <
0.0001 by unpaired student’s t-tests.

123

Figure 5.5. Effects of Cas9 + gRNA-1 on SCD erythroblasts.
Peripheral blood CD34+ cells from three SCD patients with HbSS genotype were
transduced lentivirus expressing Cas9 or Cas9/gRNA-1, enriched by FACS for mCherry
fluorescence, and cultured under conditions that favor erythroid maturation. After 21
days of culture, cells were analyzed by flow cytometry. Representative plots from three
experiments are shown with mean values ± SE. (a) Hoechst staining to distinguish
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nucleated erythroblasts from anucleate reticulocytes (black boxes). (b) HbF
immunostaining cells (“F-cells”, black boxes). Numbers in the flow cytometry plots for
panels (a) and (b) indicate mean ± SE for three independent experiments. Numbering
below the plots in panel (b) indicates HPLC determination of %HbF for one experiment.
* P < 0.05, ns = not significant, unpaired student’s t-tests.
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Figure 5.5. Genome editing inhibits sickling in vitro.
(a) CD34+ cells from an SCD (HbSS) patient were transduced with lentivirus expressing
Cas9 ± gRNA-1, differentiated into RBCs, and cultured in 2% O2.Red arrows denote cells
with sickle-like morphology. Original magnification, 200×. Size bars indicate 20 µm.
(b) Quantification of hypoxia-induced sickled cells depicted in panel (a). Mean ± SE
from three experiments using CD34+ cells from three different SCD donors (> 1,000 cells
scored per experiment).
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Figure 5.6. HBG1 and HBG2 promoter mutation analysis of CD34+ HSPC-derived
erythroblasts transduced with Cas9/gRNA-1 lentivirus.
(a) PCR amplification design for the target region, not drawn to scale. The scissors
represent the gRNA-1 cleavage site upstream of both HBG1 and HBG2 genes. The half
arrows denote PCR primers used to amplify the target regions. The red primers amplify
both HBG1 and HBG2 nonspecifically. The orange and blue primers specifically amplify
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HBG1 or HBG2, respectively. (b) Cell sorting scheme to isolate low, intermediate, and
high HbF-expressing CD235+ erythroblasts that were analyzed further according to main
Figure 5.8 and in panel (c) of this figure. Rep4 was gated into two populations, HbF-low
and HbF-high, as indicated by the dashed gray box. The indicated percentages refer to
rep1 shown in Figure 5.8. Cells were fractionated at d16 of erythroid culture. (c) Results
of replicates (rep 1-4) for the experiment in this Figure and in main Fig. 2a. The DNA
surrounding the predicted Cas9-gRNA cleavage sites in HBG1/HBG2 were amplified by
PCR (red primers in panel (a)) and analyzed by next generation sequencing. Overall indel
frequencies for unfractionated cells were 65% (rep2) and 77% (rep3). The wild type
sequence for HBG1/HBG2 is shown at the top left, above the 9 most common mutant
alleles. The gray box shows the 13-nt HPFH deletion and tandem 8-nt repeats are shown
by blue half arrows. The CCAAT box is shown in red. The 9 most common mutated
alleles are shown below, with dashes indicating deleted nucleotides and lower-case letters
indicating insertions. Mutant allele frequencies are expressed as percentages of all alleles,
shown at right.
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Figure 5.7. Spectrum of γ-globin-inducing mutations caused by Cas9 and gRNA-1.
(a) Normal adult CD34+ cells were edited with Cas9/gRNA-1 lentivirus, differentiated
into RBCs, FACS-purified according to HbF immunostaining intensity (low, intermediate
or high) and analyzed for on-target mutations. The wild type sequence is shown on the
top left with the 13-nt HPFH deletion boxed and the CCAAT box in red. Dark blue half
arrows show flanking 8-nt repeats; light blue show the DR element. The top nine mutant
alleles (of more than 40 total indels identified) are shown below. Dashes indicate
nucleotide deletions and lower-case letters insertions. In the graph at right, black dots
denote the 13-nt HPFH deletion, which occurred at the highest frequency; gray squares
show the combined frequencies of the eight next common mutations. Each symbol
represents an independent experiment. * P < 0.05, ** P < 0.01 by unpaired t-test.
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Figure 5.8. Mutation rates in BFU-E colonies correlates positively with γ-globin
expression.
CD34+ cells were electroporated with Cas9/gRNA-1/GFP expression plasmids. GFP+
cells were FACS purified and seeded into methylcellulose. Burst forming unit-erythroid
(BFU-E) colonies were analyzed for globin mRNAs and HBG1/HBG2 mutations. All
colonies were mosaic for mutations; the total HBG [(HBG1 + HBG2)/2 × 100] mutation
frequency for each colony is plotted against %HBG1/2 mRNA [γ / (γ + β)]. Regression
analysis shows best-fit line as solid gray (y = 0.82x + 4.8, r2 = 0.41, P < 0.0001, n = 35
colonies from three experiments) and 95% confidence intervals as dashed gray.
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Figure 5.9. Analysis of burst forming unit-erythroid (BFU-E) colonies derived from
transiently edited CD34+ HSPCs.
CD34+ HSPCs were electroporated with 10 µg gRNA-1/Cas9/GFP plasmid. GFP+ cells
were enriched by FACS and cultured in methylcellulose with erythroid-promoting
cytokines. Of 344 individual colonies evaluated for HBG1 and HBG2 mutations, we
detected mutations in 30. The wild type sequence is depicted at the top right, with the
13-nt HPFH deletion boxed. Specific mutations identified in each colony are shown
below the wild type sequence. Dashes denote deleted nucleotides, and lower-case denotes
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inserted bases. Frequencies for all detected mutations are expressed as percentages of all
alleles.
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Figure 5.10. HUDEP-2 clones with CCAAT box mutations demonstrate high HbF
expression.
(a) HUDEP-2 cells were electroporated with Cas9/gRNA-1/GFP plasmid and cloned.
HbF immunostaining is shown for two representative clones with different mutations (see
also panel (d) and Figure 5.12).
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(b-c) Characterization of genome edited HUDEP-2 clones. The HBG1 and HBG2
genotypes corresponding to each clone is shown on the right, according to the convention
used in panel (a); all clones are homogenous for the indicated mutations. *** P < 0.001,
**** P < 0.0001, ns = not significant by unpaired t-test.
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Figure 5.11. Analysis of genome-edited HUDEP-2 clones.
HUDEP-2 cells were electroporated with DNA plasmid encoding Cas9/gRNA-1/GFP.
Single GFP+ cells were sorted into 96-well plates after 24h and expanded. Clones were
analyzed for HBG1/2 mutations and HbF immunostaining. Of 47 clones examined, 70%
were mosaic for HBG1 and 2 mutations. Four mosaic clones were sub-cloned to generate
clones 1.1, 2.1, 3.1 (also shown in main Figure 5.11) and 4.1 (shown here). (a) Clone 9 is
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a mosaic with a bi-modal distribution of HbF immunostaining cells. (b) Analysis of
clonal populations for HBG1 and HBG2 mutations, HbF immunostaining and %HBG1/2
(γ-globin) mRNA [γ/(γ + β)]. Dashes indicate deleted nt. Lower-case letters indicate base
insertions. Clones 5-6 contain the indicated mutations in all cells and were not subcloned. Clones 7-8 are shown as examples of mosaic clones. Clones 4.1 and 5 are
heterozygous and homozygous for a 5.2-kb deletion between Cas9/gRNA-1 cleavage
sites in the HBG1/2 promoters. Clone 6 had a normal copy number in the same qPCR
assay but may have a deletion hundreds of nt long that prevents PCR/sequencing
detection, yet preserves the qPCR primer/probe sites.
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Figure 5.12. Deletion analysis of Cas9/gRNA-1 edited HUDEP-2 cells.
Cells were electroporated with DNA plasmid encoding Cas9/gRNA-1/GFP. After 24h,
GFP+ cells were FACS-purified and analyzed. (a) Map of HBG2 and HBG1 showing
cleavage sites for Cas9/gRNA-1 (scissors). Fluorescence in situ hybridization (FISH) and
quantitative real-time PCR (qRT-PCR) were used to detect deletion of the intervening
5.2-kb region. (b) FISH analysis of edited HUDEP-2 cells using the 5.2-kb probe
depicted in panel (a). The control probe detects the downstream HBB gene. No 5.2-kb
deletions were detected in 25 metaphase cells analyzed from each group. Loss of 5.2-kb
FISH probe signal was observed for a clone homozygous for the 5.2-kb deletion (clone 5,
Supplementary Fig. 6).
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Figure 5.13. Deletional analysis of Cas9/gRNA-1 edited HUDEP-2 and CD34+ cells.
(a) qRT-PCR analysis for the 5.2-kb deletion in edited HUDEP-2 cells. Black bars
indicate wild type control cells. Gray bars indicate HUDEP-2 lines that are heterozygous
(wt/del) or homozygous (del/del) for the deletion, corresponding to clones 4.1 and 5,
respectively, described in Supplementary Fig. 6. Blue bars indicate HUDEP-2 cells
electroporated with 2 µg or 10 µg Cas9/gRNA-1 plasmid. Representative results are
shown from two experiments; values are normalized to wild type HUDEP-2 cells. (b)
Deletion analysis after transient Cas9/gRNA-1 expression in human CD34+ cells. Dark
and light blue bars represent HSPCs electroporated with 10 µg DNA encoding
Cas9/gRNA-1/GFP or Cas9/gRNA-2/GFP, respectively.
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Tables

Table 5.1. Predicted gRNA-1 off-target sites assessed by deep sequencing.
Potential off-target sites were predicted using the Sanger off-target prediction tool:
http://www.sanger.ac.uk/htgt/wge/find_off_targets_by_seq. The top 15 off-target sites
predicted by nucleotide homology are shown, with mismatched nucleotides in red. To
evaluate potential off-targeting at these loci, human CD34+ cells were transduced with
lentivirus encoding Cas9, gRNA-1, and mCherry. FACS was performed to enrich for
mCherry-positive, infected cells, which were then cultured in erythroid-promoting
cytokines. Genomic DNA from erythroblasts from untransduced cells (mock) and cells
infected with Cas9/gRNA-1 was extracted and used as template to amplify the DNA
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surrounding the top 15 candidate sites shown. Coverage for each amplicon is shown at
right, and no mutant alleles were detected for any amplicon.
For a full list of predicted off-targets:
http://www.sanger.ac.uk/htgt/wge/crispr/1077773870
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Chapter 6 Conclusions and Future Directions
6.1 The role of Trim58 in terminal erythropoiesis
In the first set of studies, I investigate the role of an erythroid-specific E3
ubiquitin ligase, Trim58, which is highly induced during terminal erythropoiesis. We
found that Trim58 mediates proteasomal degradation of dynein in maturing erythroblasts,
and our analysis of Trim58-deficient cells suggested that Trim58 was necessary for
erythroid enucleation. We extended our initial studies by disrupting the Trim58 gene in
mice to investigate its role in dynein degradation and erythropoiesis in vivo. The gene
targeting strategy removed exon 3, which encodes a coiled-coil domain predicted to
participate in protein oligomerization (Koliopoulos et al., 2016; Sanchez et al., 2014;
Streich et al., 2013). Ablation of exon 3 maintains the Trim58 mRNA reading frame and
therefore could produce an internally deleted protein lacking only the coiled-coil motif
(Trim58 ΔCC, Figure 2S). However, homozygous mutant erythroblasts contained only
trace amounts of Trim58 ΔCC mRNA and no detectable Trim58 protein. Thus, the gene
targeting likely produced a null allele in RBCs. Although it was possible to express
Trim58 ΔCC in heterologous cells, the mutant protein was unable to degrade dynein,
demonstrating that the coiled-coil domain is necessary for ubiquitin ligase activity, as
observed for other Trim protein family members (Koliopoulos et al., 2016; Sanchez et al.,
2014; Streich et al., 2013). Erythroid cells from Trim58-/- mice expressed dynein at
abnormally high levels, which resulted in mildly altered MCV and RBC number, but no
anemia, hemolysis or altered recovery after phenylhydrazine-induced hemolytic anemia.
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Therefore, loss of Trim58 and failure to eliminate dynein are largely dispensable for
erythropoiesis.

6.1.1 Reconciling in vitro and in vivo systems
Previously, we showed that Trim58 shRNAs delayed the kinetics of enucleation in
cultured primary erythroblasts. However, our in vivo results demonstrate this process to
be normal in Trim58-/- erythroblasts. Moreover, Trim58 shRNAs delayed enucleation
similarly in C57Bl/6 and CD1 (but not mixed Sv129/FVB/C57Bl/6) Trim58+/+ and
Trim58-/- erythroblasts, indicating that this shRNA effect was strain-specific and
independent of Trim58 silencing. shRNAs can cause off-target effects by interacting with
mRNAs via partial complementarity. However, this mechanism is unlikely since multiple
non-overlapping Trim58 shRNAs inhibited enucleation (Jackson et al., 2006).
More plausible explanations include shRNA-induced interferon response (Jackson
and Linsley, 2004) or saturation of endogenous RNA processing pathways by high levels
of virally expressed shRNAs with consequent inhibition of cellular microRNAs. In
hepatocytes, this effect occurs partly via inhibition of exportin-5, which mediates nuclear
export of shRNAs and microRNAs (Grimm et al., 2006). Late stage erythroblasts may be
particularly susceptible to oversaturation of microRNA/shRNA processing proteins as the
proteome complexity progressively declines. In fact, numerous aspects of erythroid
maturation, including enucleation, are regulated by endogenous microRNAs (Rouzbeh et
al., 2015; Zhang et al., 2011; Zhao et al., 2010), even as exportin-5 level declines
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(Hattangadi et al., 2014). Moreover, most shRNAs expressed to sufficient levels,
including controls, inhibit enucleation of cultured erythroblasts (Paralkar et al., 2014).

6.1.2 Are erythroid cells sensitive to generalized miRNA inhibition?
Our unexpected results have led us to hypothesize that specific components of the
miRNA machinery may be dose-limiting in terminally differentiating erythroblasts. A
miRNA-sequencing study in erythroid cells at different stages of development
demonstrated that most miRNAs are downregulated during erythropoiesis. While we
predict that most miRNAs with this pattern of expression would remain unaffected by
limited reserves of miRNA machinery, several important miRNAs are highly induced
during erythroid maturation. miR-144 and miR-451 are transcribed from a bicistronic
locus, and both are highly expressed in mature erythroid cells (Yu et al., 2010). In fact,
miR-451 is the most abundant miRNA expressed, accounting for 58% of all miRNAs at
the Ter119+ stage (Zhang et al., 2011). We plan to assess the effects of varying levels of
shRNA expression on both endogenous production and downstream processing of miR144 and miR-451. Interestingly, miR-451 processing is Dicer-independent (Cheloufi et
al., 2010; Cifuentes et al., 2010), so altered levels of mature miR-451 would help
pinpoint the rate-limiting factor pathway. While further studies are required to define the
exact mechanism by which Trim58 shRNAs inhibit erythroblast enucleation, our
observations indicate that the effects of any shRNAs on erythroid maturation must be
interpreted with caution and validated through alternate lines of investigation. This
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particular line of investigation becomes clinically important with the proposed gene
therapy approach using shRNAs targeting BCL11A specifically in erythroid cells to
induce fetal hemoglobin (see Chapter 1.5) (Guda et al., 2015).

6.1.3 The role of dynein degradation in hematopoiesis
Our results in Chapters 3 and 4 are consistent in demonstrating that Trim58
mediates degradation of dynein, a multi-subunit molecular motor complex that transports
organelles and proteins along microtubules, usually in a minus direction (toward the
centromere). Dynein participates in essential cellular processes including mitosis and
organelle positioning and is necessary for the proliferation of erythroid precursors and
their subsequent enucleation (Kobayashi et al., 2016). Thus, it is puzzling as to why
Trim58 expression is induced during late stage erythropoiesis when dynein is necessary
for these processes. Perhaps the unique maturation of this cell type is sensitive to dynein
levels, which Trim58 helps to fine tune. In this regard, dynein levels may regulate
erythroid MCV by influencing specialized cell divisions of late stage erythroid
precursors, which are associated with shortened G1 phase and progressively reduced cell
volume (Dolznig et al., 1995; Grebien et al., 2005). This process is modulated by the
levels of Cyclin D3 (Sankaran et al., 2012) and Cyclin A2 (Ludwig et al., 2015) whose
corresponding genes (CCND3 and CCND2A), like TRIM58, were discovered by GWAS
to regulate erythroid MCV (Ganesh et al., 2009; Kamatani et al., 2010; van der Harst et
al., 2012). During thrombopoiesis, Trim58 expression may influence the rates of dynein145

dependent proplatelet formation and maturation to regulate platelet size and number. In
any case, the timing and levels of Trim58 induction during erythroid and megakaryocyte
maturation must be regulated precisely so as to preserve dynein for general and
specialized cellular processes. In agreement, retroviral expression of Trim58 in erythroid
precursors removed dynein prematurely and induced cell death (Thom et al., 2014).
While premature depletion of dynein is likely deleterious to erythropoiesis, the
current study shows that abnormally elevated dynein does not impair erythroid
maturation, although in principle its excessive activity could alter the trafficking of
cellular organelles. However, we found no evidence for erythroblast enucleation defects
or abnormal distribution of lysosomes and mitochondria in Trim58-/- reticulocytes (not
shown). During erythroblast enucleation, the microtubule network partially collapses and
segregates with the nascent reticulocyte (Thom et al., 2014). Shortly thereafter, the UPS
degrades residual microtubules (Chasis et al., 1989), and we were unable to detect them
by α-tubulin immunostaining of circulating Trim58+/+ or Trim58-/- mouse reticulocytes
(not shown). Thus, while dynein is expressed at abnormally high level in Trim58-/reticulocytes and RBCs, it is probably inactive without microtubules and not toxic.
From the work in Chapter 3, we formulated two models to explain the regulation
of dynein protein levels during enucleation (Figure 3.17): 1) dynein suppression was
necessary to create a molecular motor imbalance, allowing the plus end-directed actions
of kinesins to polarize the nucleus away from the MTOC; and 2) Trim58-mediated
dynein degradation destabilized microtubules and promoted their detachment from both
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the cell cortex and nuclear membrane (i.e. microtubule cage collapse) (Hendricks et al.,
2012). The former model was supported by studies performed in other cell types,
including muscles and neurons (McKenney et al., 2010; Splinter et al., 2010; Tanenbaum
et al., 2011; Tsai et al., 2010; Wilson and Holzbaur, 2012). In addition, dynein
coordinates mitosis by mediating chromosome movements, spindle organization, and
spindle positioning (Sharp et al., 2000; Howell et al., 2001;Varma et al., 2008). Data in
Chapter 4 suggest these mechanisms are not dysregulated sufficiently disrupt
erythropoiesis. Dynein excess, as observed in Trim58-/- erythroid cells, could potentially
delay these processes and mitotic progression, consequently resulting in mild changes in
RBC size and number.

Does Trim58 regulate megakaryocyte and platelet function?
Of note, Trim58 is also expressed in megakaryocytes (Pimkin et al., 2014). The
platelet count trended downward in Trim58-/- mice, although this did not reach statistical
significance. Dynein-dependent sliding of antiparallel microtubules is required for the
extension of proplatelets from megakaryocytes and subsequent platelet formation
(Bender et al., 2015; Patel et al., 2005). Dynein is also involved in platelet activation by
inhibiting contraction of the marginal band, a ring-shaped network of microtubules on the
periphery of platelets (Diagouraga et al., 2014). Therefore, Trim58 could potentially
influence platelet production and size by modulating dynein expression in these cells. In
agreement with the latter, GWAS links TRIM58 to circulating platelet counts. Our results
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suggest that rather than platelet count, Trim58 may affect the function of megakaryocytes
and platelets. Alpha and dense granules are membrane-bound organelles, containing
platelet-activating factors including von Willebrand factor and serotonin, which are
actively translocated along microtubules and sorted into proplatelets (Richardson et al.,
2005). These granules are secreted upon platelet activation to promote stability of a clot
at a site of blood vessel injury. Trim58 may, therefore, function in megakaryocytes to
limit granule delivery. Further studies are required to investigate whether Trim58-/- mice
exhibited altered dynein levels in megakaryocytes and platelets and the consequent
effects on formation and function of the latter.

6.1.4. Lessons from GWAS
Genome wide association studies identify nucleotide polymorphisms that
associate with traits of interest and typically ascribe causality to altered function or
expression of the nearest gene. However, causal genetic variants that impact cell traits
frequently modify transcriptional regulatory elements (enhancers), which can potentially
influence the expression of distant genes (Ulirsch et al., 2016). Therefore, GWAS
findings must be verified by functional studies to identify and characterize the relevant
involved gene. Approximately 75 candidate genes that regulate RBC traits have been
identified by GWAS (Ganesh et al., 2009; Kamatani et al., 2010; van der Harst et al.,
2012). Follow-up studies have elucidated new aspects of erythroid physiology, including
regulation of cell size (CCND3 and CCND2A) (Ludwig et al., 2015; Sankaran et al.,
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2012), erythroblast proliferation (SH2B3) (Giani et al., 2015), RNA splicing (RBM38)
(Ulirsch et al., 2016), and fetal hemoglobin production (BCL11A and MYB) (Bauer et al.,
2013; Lettre et al., 2008; Sankaran et al., 2008a). The current study demonstrates that loss
of Trim58 expression alters MCV and RBC number, consistent with previous GWAS
linking the human TRIM58 gene to the same RBC traits, and providing a potential
mechanism by showing that Trim58 is a ubiquitin ligase that facilitates dynein
degradation. Of note, the effect magnitude of Trim58 ablation in mice was approximately
27- and 67-fold greater for MCV and RBC number, respectively, compared to the effect
magnitudes associated with human TRIM58 variant alleles (see Chapter 2), which likely
cause subtle alterations in protein expression or function.
Why complete loss of Trim58 in mice and a subtle alteration of TRIM58 in
humans produce similar mild effects on RBCs (and perhaps platelets) is unknown. One
potential explanation may be that non-redundant requirements for TRIM58 are greater in
human erythropoiesis compared to mice. Gene expression in mice and human
erythroblasts are surprisingly discordant, with potential functional consequences (An et
al., 2014; Pishesha et al., 2014). For example, mutations in the protein secretory
transporter gene SEC23B cause congenital dyserythropoietic anemia in humans, while
Sec23b knockout mice exhibit normal erythropoiesis (Khoriaty et al., 2014). It is also
possible that enhanced TRIM58 activity conferred by human genetic variation, with
consequent lowering of dynein levels, exerts more profound effects on erythroid
maturation than loss of Trim58 with abnormal dynein retention. In this case, complete
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loss of Trim58 in mice would produce relatively small effects on RBC number and MCV
(as observed), while effects of similar magnitude in the opposite direction could result
from more subtle alterations in TRIM58 caused by naturally occurring allelic variants.
Regardless, our studies confirm human GWAS by demonstrating that Trim58 regulates
RBC traits. However, Trim58 is not essential for generating these cells in mice, but
rather, serves to fine-tune their terminal maturation, possibly by restricting dynein levels.
It is also possible that Trim58 function is redundant with other E3 ubiquitin
ligases or other protein degradation pathways. Germline knockout of Trim58 might allow
gene expression changes during development permitting Trim58-/- mice to compensate
for gene dosage. This effect has been reported when comparing phenotypes observed
with RNAi-mediated knockdown or morpholino versus genetic ablation (Rossi et al.,
2015). To begin to address these questions, we performed microarray transcriptome
profiling, comparing Ter119+ fetal liver erythroblasts from Trim58+/+ and Trim58-/- E14.5
embryos (not shown). Outside of Trim58, we did not identify any genes with significant,
differential expression between the two groups.

These data support the former

hypothesis, where the UPS is highly critical, and overlapping pathways exist at steady
state to protect against loss of a single element. Another Trim protein, Trim10, previously
shown to mirror the expression pattern of Trim58 in erythroid cell lines (Blaybel et al.,
2008; Harada et al., 1999). Like Trim58-/- mice, Trim10-/- mice also do not show
obviously aberrant erythropoiesis (personal communication, J. Downing). Future work
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will investigate this by interbreeding mouse models, as it is possible that multiple
components of the UPS pathway need to be mutated to affect the erythroid compartment.

6.2. Genome editing the γ-globin promoters
In Chapter 5, we tested the hypothesis that CRISPR-Cas9 could generate
mutations in the HBG1 and HBG2 promoters that would recapitulate the effects of a 13-nt
HPFH deletion in human hematopoetic stem and progenitor cells (HSPCs). We chose to
target this locus mainly for the technical advantage of the mutation being small. We
predicted that targeting the mutation would require a single gRNA and would also be
generated at a higher frequency. The observed deletion efficiency with a pair of gRNAs
is inversely related to the size of the large deletion (Canver et al., 2014). We found that
lentiviral-mediated editing of CD34+ HSPCs and an erythroid cell line, HUDEP-2, indeed
caused phenotypes of HPFH. Importantly, edited erythroblasts underwent normal
erythroid differentiation and maturation, suggesting that defects in or delayed
erythropoiesis was not responsible for γ-globin induction. Furthermore, we explored the
feasibility of targeting the γ-globin promoters in proof-of-concept experiments using
SCD patient-derived HSPCs. Our data show that genome editing reduced in vitro sickling
by about 75% and support -102 to -114 of the HBG promoters as potential DNA targets
for therapeutic genome editing for β thalassemia and SCD.
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6.2.1 Therapeutic genome editing for SCD
In the context of therapy development, genome-editing technologies to
manipulate hematopoietic stem cells have dramatically fueled innovative strategies for
treating β thalassemia and SCD. Homology-directed recombination (HDR)-mediated
correction of the SCD mutation is perhaps the most theoretically direct approach,
involving an extra-chromosomal template to serve as the wild type allele. The main
limitation of this approach is the relatively inefficiency in HPSCs. Hoban et al. recently
reported in vitro mutation correction rates of 20% in CD34+ HSPCs using a targeting
zinc-finger nuclease and integration-deficient lentivirus encoding template for repair
(Hoban et al., 2015). However, after transplanting the human cells into a xenograft mouse
model, the corrected allele frequency plummeted below 1% in vivo. Additionally, failed
HDR does not preclude a successful double-stranded break at the target site, which could
produce unintended insertions and deletions in HBB and potentially loss-of-function βglobin alleles (Canver et al., 2014). A more attractive strategy is disrupting the erythroidspecific enhancer element of BCL11A (Bauer et al., 2013; Canver et al., 2015; Xu et al.,
2011). In either of these therapies, HSPCs will be isolated from subjects, edited ex vivo,
and then returned to the same individuals via autologous bone marrow transplantation.
Advantages of targeting the enhancer are numerous: 1) NHEJ-induced indels are likely to
disrupt the enhancer function; 2) human life is tolerant to genetic variation in the
enhancer (as evidenced by GWAS); and 3) mutations potently induce HbF.
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Our experiments show that CRISPR/Cas9-mediated disruption of the HBG
promoter CCAAT box induces HbF to similar levels achieved by genome editing the
BCL11A enhancer. Perhaps the greatest strength of our approach is that we recreate a
mutation that is carried by normal, healthy individuals with HPFH. With any of the
proposed genome editing strategies for hemoglobinopathies, future efforts will focus on
optimizing delivery and on-target editing in long-term repopulating stem cells. Whereas
the majority of our experiments utilized lentiviral delivery of gRNA/Cas9, genome
editing for therapy would need to be transient to avoid the continued, lifelong genome
editing in hematopoietic stem cells. Currently, transient expression techniques for
suspension cells require electroporation (DNA, RNA, or protein) or an integrationdefective lentivirus (Kim and Kim, 2014). Recent work suggested by electroporation of
Cas9 complexes pre-loaded with gRNA preserves the viability of CD34+ cells, but
studies are necessary to demonstrate that a sub-population of HSCs are edited and can
repopulate bone marrow niche (Hendel et al., 2015). A promising, yet untested approach
for any suspension cells or HSPCs is a protein transduction method that utilizes a
combination of NaCl hypertonicity-induced macropinocytosis and propanebetaine to
allow cellular uptake of proteins from the environment (D'Astolfo et al., 2015).
Furthermore, it is not yet known which set of genome editing tools would be most
efficient to target -102 to -114 of the γ-globin promoters. Zinc finger nucleases and
TALENs (Transcription Activator-Like Effector Nucleases) should also be tested in
parallel to directly compare the on-target editing rates in stem cells. These efficiencies
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would be evaluated in an immunodeficient xenograft mouse model (NOD.CgPrkdSCIDIl2rgtm1Wjil/SzJ (NSG)), which allows the engraftment of human HSCs.
Xenograft mouse models are suboptimal for functional assessments and fetal hemoglobin
production because human-derived erythroblasts fail to develop in these mice. However,
evaluation of the editing rates in human cells after 12 weeks will demonstrate the editing
efficiency in long-term repopulating HSCs.

Off-target effects
Genome editing approaches remain untested in patients and numerous challenges
must be overcome for safe and effective clinical translation. The unpredictability and
error-prone nature of NHEJ-mediated repair poses many safety concerns. Off-target
editing is also a particular concern in CRISPR/Cas9 targeting of this locus because the
CCAAT box comprises 5 of the 20 nt in the gRNA sequence. Of note, about 30% of
randomly surveyed promoters contained a CCAAT motif (Bucher, 1990). While we
performed amplicon sequencing at off-target sites across the genome, as predicted by
bioinformatics approaches, this method is sub-optimal in sensitivity for the detection of
rare mutation events and events outside our candidate loci. An alternative method, Cas9
ChIP-sequencing, reveals the nature of Cas9 binding genome-wide, but Cas9 may simply
bind and not create a double-strand break. We plan to pursue recently developed genomewide off-target analysis called GUIDE-sequencing, where a short oligonucleotide tag
integrates at sites of DNA breaks at the time of editing (Tsai et al., 2015). PCR and
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sequencing of the tagged regions allow identification of the loci surrounding the DNA
break. These described approaches require the sensitivity to identify rare editing events
potentially anywhere in the human genome, and sequencing multiple genomes as in a
bulk pool of cells limits the sensitivity of these approaches. Therefore, we also plan to
genome edit -102 to -114 of γ-globin promoters in a humanized mouse model of SCD.
We will attempt editing hematopoietic stem cells with subsequent bone marrow
transplantation, in addition to germline editing of zygotes. In addition to assessing the
extent of SCD phenotypic rescue with editing, we will also evaluate mice for
hematopoietic neoplasms.

Extension to non-editing approaches to gene therapy
Gene therapy strategies for SCD and β thalassemia are currently in clinical trials
for β-globin gene replacement. In this approach, subjects undergo autologous bone
marrow transplantation with cells that are transduced with lentivirus encoding an antisickling form of β-globin (βT87Q). Initial results with LentiGlobin HPV569 and
LentiGlobin BB305 are highly promising – the first treated subject became and has
remained transfusion independent, now 7 years after treatment (Cavazzana-Calvo et al.,
2010). However, the following subjects with more severe forms of β thalassemia and
SCD had more varying responses to therapy. Lentiviral gene therapies to exogenously
express γ-globin are also being developed (Perumbeti et al., 2009; Pestina et al., 2009;
2015; Wilber et al., 2011). The commonalities amongst these vectors are the enhancer
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and promoter elements driving globin expression, including a mini-LCR (HS2, HS3, and
HS4) followed by the β-globin promoter. We posit that higher exogenous levels of γglobin could be achieved by utilizing the γ-globin promoter adapted with the 13-nt HPFH
deletion.

6.2.3 How does the CCAAT box repress HbF expression?
Ongoing and future studies are now focused on the mechanisms of HbF regulation
mediated by the regulatory sequence in the γ−globin promoter. In a clonal analysis of
edited HUDEP-2 cells, we showed that 1- to 4-nt deletions within the CCAAT box is
sufficient for high HbF expression. The -114 γ-globin promoter CCAAT box likely
mediates postnatal γ-to-β globin switching by recruiting transcriptional repressors in a
developmentally regulated fashion (Forget, 1998; Stamatoyannopoulos, 2005). Candidate
CCAAT box binding proteins include COUP-TFII (NR2F2, NF-E3 (Mantovani et al.,
1989; Ronchi et al., 1995))(Liberati et al., 2001), NF-Y (CP-1, CBF) (Liberati et al.,
2001; Zhu et al., 2012), CDP (Mantovani et al., 1989; Superti-Furga et al., 1988), and
C/EBP (Superti-Furga et al., 1988). An overlapping motif binds nuclear hormone
receptors TR2 and TR4 (Tanabe et al., 2002). Although the molecular triggers of γ-to-β
globin switching

are

not

fully

defined,

we

plan

to

perform

chromatin-

immunoprecipitation (ChIP) experiments to determine the occupancy of these candidate
DNA-binding proteins. We will also test whether BCL11A binding is altered by CCAAT
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box mutations by ChIP, despite the absence of a consensus sequence or previously
described ChIP signal.
Our studies suggest that altering the γ-globin promoter CCAAT box reverses the
γ−to-β switch. Instead of simply inducing γ-globin, we show that absolute levels of βglobin are concomitantly reduced. This suggests that the edited promoter region adjusts
the long-range contacts with LCR by promoting enhancer-promoter interactions with
HBG1 and HBG2, as opposed to HBB. We plan to test the nature of these interactions in
edited, high-HbF and unedited HUDEP-2 cells by performing 3C (chromosome
conformation capture)-based chromosomal interaction studies. In an extended 3C method
called Capture C, we will cross-link DNA-bound proteins in cells, restriction enzyme
digest the genome, and ligate fragments that are in spatial proximity to one another. We
will build sequencing libraries and enrich for sequences interacting with the LCR by
performing a nucleotide capture step with biotinylated oligonucleotide probes (Hughes et
al., 2013; 2014).
Deng et al. have shown that forcing the chromatin to form a loop between the
LCR and the γ-globin promoter raised HbF and commensurately reduced β-globin
expression (Deng et al., 2014). Interestingly, the zinc finger domains used in this study
target a region 1 nt upstream of the 13-nt HPFH deletion (Wilber et al., 2011). It is
possible that the CCAAT box is merely part of the nucleotide sequence required γ-globin
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repression, and that mutagenesis of the CCAAT box sufficiently removes the critical
DNA-binding sites for either looping factors or transcriptional repressors.

6.2.4 Identifying additional cis-regulatory elements
We isolated several HbF-high HUDEP-2 clones in which simultaneous Cas9gRNA-induced DNA breaks in both promoters of HBG1 and HBG2 caused deletion of
the intervening 5.2-kb sequence. While the occurrence of the intervening deletion was
predicted based on gRNA recognition of the duplicated promoters regions, the high-HbF
phenotypes of these clones was a surprising finding. The 5.2-kb deletion generated
removes the entire HBG2 gene. One hypothesis to explain the effects of the large deletion
de-represses γ-globin is the removal of an additional negative regulatory element lying
within HBG2 (intronic) or between (intergenic) HBG1 and HBG2. We plan to investigate
this further by generating and analyzing HUDEP-2 clones with a series of deletions in the
region to identify critical sequences. Identifying and studying novel regulatory sequences
will elucidate new mechanisms of γ-globin regulation and potential therapeutic targets.

6.3 Concluding remarks
In this thesis, we have leveraged insights from human genetic variation to perform
focused studies on two different aspects of erythroid biology. In Chapters 3 and 4, we
performed follow-up experiments to test the hypothesis that GWAS inspired – that SNPs
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in linkage disequilibrium with TRIM58 associated with deviations in RBC parameters
implicated the gene in erythroid development. In Chapter 6, we used genome-editing
techniques to recreate a rare genetic variant associated with HPFH, a condition with an
oppositely extreme effect size. While seemingly different at the surface, studies of both
Trim58 and γ-globin gene regulation also highlight the intricacies of the dynamic
expression (both at the level of transcription and protein) changes that occur during
terminal erythropoiesis. Finally, our findings provide an example of how knowledge
learned from the study of patients can provide approaches for rationally designed
therapies.
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